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The potential of growth factors to stimulate tissue healing through the enhancement of cell proliferation, mi-
gration, and differentiation is undeniable. However, critical parameters on the design of adequate carriers, such
as uncontrolled spatiotemporal presence of bioactive factors, inadequate release profiles, and supraphysiological
dosages of growth factors, have impaired the translation of these systems onto clinical practice. This review
describes the healing cascades for bone, cartilage, and osteochondral interface, highlighting the role of specific
growth factors for triggering the reactions leading to tissue regeneration. Critical criteria on the design of carriers
for controlled release of bioactive factors are also reported, focusing on the need to provide a spatiotemporal
control over the delivery and presentation of these molecules.
Introduction
The recreation and maintenance of functionallyviable tissues using tissue engineering (TE) approaches
incorporating controlled release functionalities is quite chal-
lenging due to the fact that cells respond to a wide array of
structural, biochemical, and temporal cues in a microenvi-
ronment, which is difficult to simulate.1 These stimuli work
in cooperation to assemble and organize cells and their re-
spective matrix into tissues. The concept of biomimicry relies
on the development of nature-inspired biomaterials aiming
for the generation of new tissues and organs. Biomimetic
approaches can be applied through different perspectives,
including tissue functionality, materials/composition, and
biological mechanisms, intervening in tissue formation, re-
modeling, and healing.2
This review will address the increasing level of complexity
and functionality in the design of TE approaches through the
spatiotemporal controlled delivery of bioactive factors from
three-dimensional (3D) constructs and their effect on the
skeletal tissue healing. It comprises the recapitulation of
native bone, cartilage, and osteochondral interface morpho-
genesis and healing; specifically, the sequence of events
leading to tissue regeneration and the key signaling mole-
cules involved in those processes. Moreover, the variables
involved in the design of controlled delivery systems for the
desired targeting tissues are also highlighted; specifically, the
presentation of the appropriate sequence, rate, and dosage of
bioactive factors in a spatiotemporal controlled manner.
Brief Recapitulation of Native Skeletal
Tissue Morphogenesis and Healing
There has been considerable interest in understanding the
signaling interplay in bone and cartilage due to their limited
ability to heal upon serious fracture or trauma. Bone is
comprised of a variety of cell populations, extracellular ma-
trix (ECM), and other proteins as well as inorganic compo-
nents that work synergistically to sustain physical forces,
molecular signals, and systemic hormone networks.3 On the
other hand, articular cartilage is a highly resilient connective
tissue that covers the surfaces at the ends of long bones.4 The
osteochondral tissue is a gradual transition from cartilage to
bone in which the key constituents of each tissue undergo an
exchange in predominance.5,6 Therefore, the treatment of
osteochondral lesions is even more problematic because
tissue damage involves two different tissues with different
intrinsic healing capabilities.7
Bone healing
Bone is distinguished from other tissues by the presence of
inorganic hydroxyapatite8 and a wide range of organic
components, mostly collagen type I. The mineral part con-
stitutes 65%–70% of the matrix, whereas the organic phase
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comprises the remaining 25%–30% of the matrix. From a
materials science perspective, bone can be considered as a
truly composite material.9 The mineralized collagen-based
ECM is the defining feature of bone, which provides its
unique biomechanical properties.10–13 Collagen type I can
initiate and orientate the growth of carbonated apatite min-
eral, controlling its size and 3D distribution.14–16 The com-
plex hierarchical structure, material properties of the
constituents, cellular organization, and molecular cues work
in concert to perform the function of bone.17 The hierarchical
geometrical structure of bone is critical, not only for the
macroscopic mechanical properties, but also for cells, which
respond to these by converting mechanical and architectural
cues into intracellular signals, which drive activities, such as
gene expression, protein production, and general phenotypic
behavior.17–22
Upon injury, bone tissue presents the ability to self-repair,
in contrast to soft tissue that heals by forming scar tissue.23,24
The vast majority of defects heals on their own or recovers
after standard orthopedic procedures.25,26 Surgical treat-
ments of bone defects typically fall into two groups: the Ili-
zarov method27 and the bone graft transplant.28 Although
the Ilizarov method—osteotomy followed by bone distrac-
tion—takes advantage of the regeneration potential of bone,
it is a highly inconvenient procedure for the patient.29 Over
the last decades, the medical field has advanced dramatically
in the understanding of tissue and organ healing and re-
pair.30 Transplantation of organs or tissues is still a common
accepted methodology to treat patients and tissue replace-
ments, such as autografts,31–33 allografts,34–36 xenografts,37–39
and graft substitutes,40–42 are clinically available therapies to
restore the tissue structure and function.43 However, the
current situation is suboptimal at best44,45 with the current
grafting methodologies presenting several and obvious lim-
itations, including lack of donors,46 donor-site morbidity,47
complicated surgical procedures,48 immune rejection,49
chronic inflammation,50 and lack of clinical predictability.51
However, extreme situations, such as compromised wound
environment,44,52 biomechanical instability,45,53 or insuffi-
cient surgical techniques,54,55 might lead to large defects with
limited intrinsic regeneration potential, often designated as
critical size defects. In these cases, complete regeneration
cannot occur.25,56
Bone metabolism is a complex process regulated by a large
number of bioactive molecules, and bone repair is, to a large
extent, a recapitulation of developmental events.57,58 During
the fracture repair process, cells progress through stages of
differentiation reminiscent of those that cells undergo during
normal fetal bone development.26 Four stages of bone repair
have been described, as shown in Figure 1: (1) immediate
postfracture (day 1–2). Trauma leads to the activation of the
local host response, with the activation and influx of in-
flammatory cells and secretion of various mediators, leading
to the formation of hematoma. This process is necessary for
the initiation of tissue repair and wound healing59; (2) in-
tramembranous ossification (days 3–5). Immune cells stim-
ulate cell division of osteochondrogenitors and fibroblast-like
cells in the cambium layer of periosteum60; (3) chondrogen-
esis (days 6–9), through the proliferation of chondrocytes
and production of cartilaginous matrix61 and; (4) endo-
chondral ossification (days 10–20), through the production of
mineralized ECM and vascularization of the tissue.62,63 Al-
though overlapping occurs, there is a temporal sequence of
maximum levels of specific growth factors (GFs) and cyto-
kines.64 One of the critical aspects for bone formation is the
formation of an extensive network of blood vessels as both
intramembranous and endochondral bone ossification occur
in close proximity to vascular ingrowth.8,65 Endochondral
ossification is the process by which mesenchymal stem
cells (MSCs) differentiate toward chondrocytes, producing a
cartilaginous template, which contributes to longitudinal
growth of the majority of bones and is gradually replaced
by bone and marrow. During this process, chondrocytes
proliferate, undergo hypertrophy, and die. The deposited
cartilage ECM is invaded by blood vessels, osteoclasts, bone
marrow MSCs (BMSCs) and osteoblasts and deposition
of mineralized ECM is initiated.66,67 On the other hand,
intramembranous ossification occurs in the absence of a
cartilage template, whereby bone develops directly from
mesenchymal progenitors.67,68
FIG. 1. Stages of bone healing upon fracture/injury, which
can be divided in five main steps: inflammation, in-
tramembranous ossification, chondrogenesis, endochondral
ossification, and remodeling. In more detail, after injury (i),
bone undergoes an induction stage where there is an influx
of inflammatory cells and occurs the formation of hematoma,
as shown in (ii). Gray areas represent necrotic bone tissue.
Afterward, during inflammation, occurs the formation of a
cartilage intermediate, as it can be observed by the gray area
in (iii). Stage (iv) represents the formation of the soft callus, in
which a chondrogenic matrix unites the defect area. From
this moment, ossification occurs and woven bone replaces
the temporary cartilaginous template through the invasion of
blood vessels (stage (v)) and finally, remodeling occurs in
step (vi) with lamellar bone promoting the union of the de-
fects and the medullar cavity being restored. Adapted from
refs.68,69 Color images available online at www.liebertpub
.com/teb
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Bone formation is comprised of series of cellular events,
which include (1) chemotaxis of osteoblast precursors to the
sites of resorption defects69,70; (2) proliferation of these pre-
cursors to form a team of osteoblasts capable of filling in
the resorption defect71,72 followed by (3) differentiation of the
preosteoblasts to form mature cells, which are responsible for
expressing the structural proteins of bone, such as collagen
type I and other functional proteins.67,73–75
Bone biochemical environment permits and promotes
cellular functions that lead to matrix production and ossifi-
cation.76 The matrix is an active and dynamic biochemical
system, including important regulatory cues to nearby cells,
affecting gene expression and changes at the cytostructural
level.76 There are several mobile (GFs, transcription factors,
and cytokines)77–83 and immobilized (collagen type I, fibro-
nectin, decorin, and biglycan)84–89 macromolecules in the
bone ECM directing bone cells behavior. Some of the most
important soluble mobile macromolecules include the
platelet-derived growth factor (PDGF),90 Bone morphoge-
netic protein (BMP),91 Insulin growth factor (IGF),92 and
transfoming growth factor (TGF).93 In addition to minerali-
zation, osteoblasts produce a matrix of proteins that not only
serve to structurally support cells, but also to provide a va-
riety of chemical cues, which regulate functionality, namely,
the ability to promote mineralization.17,94–96 The most
abundant protein is collagen type I, which besides playing
the main role in the tensile properties of bone, also contains
peptides, which cue bone cells.97 The most abundant non-
collagenous bone ECM protein is osteonectin, known for its
multiple calcium and collagen binding sites. Moreover, it has
been shown to be a potential nucleator of hydroxyapa-
tite.17,98,99 The second most abundant noncollagenous pro-
tein in bone ECM is osteocalcin, which presents affinity for
calcium/hydroxyapatite and has also been involved in the
osteoclast migration process.17,100
Inflammation is also a key component of the early re-
sponse to bone injury.101,102 Inflammatory cells are recruited
to the damaged bone and release cytokines, chemokines, and
GFs that amplify the process.103 Inflammation in the early
phase of fracture repair is associated with enhanced healing,
while chronic inflammation has a deleterious effect on
healing.3 Following implantation of materials, inflammatory
responses are also expected. The host initiates a physiological
healing reaction, consisting first of an acute inflammatory
response followed by repair processes.104,105 This inflamma-
tory stage provides the appropriate signals for the shift from
inflammation to repair and remodeling of the tissue.106–108
The extent or degree of the inflammatory response is con-
trolled by the extent of injury in the implantation procedure,
by the tissue or organ into which the device is implanted and
the extent of provisional matrix formation.107 The initial
week-long inflammatory phase of fracture healing is charac-
terized by the influx of inflammatory cells, that is, neutro-
phils, lymphocytes, and macrophages and the release of
various cytokines and GFs.109 The inflammation process
constitutes the fundamental difference between development
and regeneration.26 Therefore, modulation of inflammation
has been an increasingly used strategy to control tissue re-
generation.110 When delivering cytokines, precise spatial and
temporal control over the delivery profile is required because
both prolonging and obliterating signaling might impair bone
healing.109
There is a close inter-relationship between bone healing
and formation of the vascular compartment. The clinical
significance of angiogenesis in bone regeneration is of ut-
termost importance as an appropriate blood supply has been
recognized as an essential component of normal fracture
healing.111,112 Angiogenesis, the growth of new capillary
blood vessels from pre-existing host vasculature,113 is also
involved in the initiation of fracture healing and promotion
of endochondral and intramembranous ossification in bone
development, through blood vessel invasion of avascular
cartilage114,115 and ingress of osteoblast progenitors,111,116,117
respectively. It involves the formation of capillary networks
by endothelial cells, thereby enabling the transport of oxygen,
nutrients, and waste throughout the tissue.118 The sufficient
supply of nutrients and oxygen to the cells transplanted into
the body is indispensable for cell survival and consequent
maintenance of their biological function.119,120 Angiogenesis
is a complex process involving endothelial cell activation,121
recruitment,122 and migration 123 to sprout the neovessels to
the mural cells (pericytes or smooth muscle cells) making up
the surrounding vessel wall for stabilization.8 All vasculari-
zation processes involve a series of interactions among
cytokines, GFs, various types of cells, and enzymes.124,125
Osteoblasts and endothelial cells cross-talk and act synergis-
tically toward the formation of a mature vascular network
and for the differentiation of osteoprogenitor cells into oste-
oblast and formation of bone ECM.3,126,127
Cartilage healing
Articular cartilage is composed by a unique type of cell,
the chondrocyte, embedded within a dense ECM consisting
of 80% water, a collagen type II network, and proteogly-
cans.128,129 Although cartilage appears to be a simple an-
eural, avascular, connective tissue, there are many levels of
complexity in its composition and structure.130,131 Both cells
and matrix distribute within successive cartilage layers
identified as superficial, transitional, radial (deep zone), and
calcified zones.29 Cartilage tissue demonstrates significant
differences in cell phenotype, composition, and matrix or-
ganization along the depth of the tissue, reflecting different
biomechanical and functional requirements of different
zones.132–134
Hyaline cartilage is characterized by its high content on
proteoglycan aggrecan, which exists in the form of proteo-
glycan aggregates in association with hyaluronan (HA) and
link protein (LP). These aggregates are responsible for the
turgid nature of cartilage, providing the osmotic properties
necessary to resist compressive loads.135,136 A variety of
small leucine-rich repeat proteoglycans (SLRPs), such as
decorin,137 biglycan,137 fibromodulin,138 and lumican,139 are
also present and contribute for the maintenance of integrity
of the tissue and to modulate its metabolism.135
The most basic functions of cartilage include providing
near frictionless surface between load bearing in the joints to
allow for pain-free motion, shock-absorbance, and load dis-
tribution.140 The avascularity of articular cartilage has led to
the assertion that the tissue is immunoprivileged, whereby
the body’s immune system is limited in its ability to detect
and reject implanted tissue.141
Numerous GFs work in concert to regulate develop-
ment and homeostasis of articular cartilage throughout life,
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in particular bioactive factors from the TGF-b super-
family,142–145 Fibroblast growth factor (FGF) family,146 and
IGF-I.147–149 Architectural design for regenerative medicine
and surgery is also an adaptation of the phenomenon
observed during development and morphogenesis.150 To
properly restore the zonal structure of cartilage, phenotypi-
cal differences between chondrocyte populations and the
response of chondrocyte subpopulations to GFs and external
stimulus should be fully understood.151
Typically, chondrocytes respond to injury caused by me-
chanical insult, joint instability, and inflammatory cytokines
through matrix activation, cell proliferation, apoptosis, and
matrix destruction.152,153 The activation of chondrocytes can
result in modulation of gene expression, resulting in different
patterns of protein synthesis, fibroblast dedifferentiation,
hypertrophy, or regeneration of mature cartilage.152 The lack
of vascular supply in cartilage limits early repair responses
upon injury.150 Consequently, injury to cartilage usually
heals through a scar tissue formation mainly composed of
fibrocartilage with inferior mechanical properties and a
gradually degrading nature.4 Moreover, cartilage has a low
cell:matrix ratio and chondrocytes have a relatively low
metabolic activity limiting the tissue remodeling activity.154
Only when the injury reaches the subchondral bone, self-
healing processes are initiated by the release of mesenchymal
progenitor cells from bone marrow into the wound site.2 This
observation forms the basis of surgical repair techniques,
such as abrasion arthroplasty,155,156 drilling,157 and micro-
fracture158 to penetrate the subchondral bone. Periosteum is
also a source of cells that can differentiate into chondrocytes
and autogenous or allogeneic cell/tissue transfer via peri-
osteal grafts159,160 has been used, while other techniques
have used chondrocytes or cartilage directly. Autologous
chondrocyte transplantation involves harvesting cells from a
noninvolved area of the joint, to expand them in culture, and
then transplanting them to the area of involvement.161–163
However, these techniques present several limitations
particularly on cell and tissue availability, unwanted fi-
brocartilage formation and inadequate graft integration.164–166
Another strategy for the regeneration of articular cartilage is
mosaicplasty and it is based on the creation of multiple small
osteochondral grafts.167–170 The limiting factor of mosaicplasty
resides in the donor-site availability of grafts.
In degenerative diseases, such as osteoporosis or rheuma-
toid arthritis, the remodeling equilibrium of cartilage is dis-
rupted and the rate of collagen and proteoglycans loss from
the matrix exceeds the rate of deposition of newly synthesized
molecules.152,171,172 The upregulation of cartilage-degrading
enzymes can be caused by several factors, such as chemokines,
other inflammatory mediators, and mechanical loading.173
Although current approaches are reasonably effective in
achieving clinical endpoints of symptomatic relief, they have
not been successful at preventing future degeneration of the
repaired tissue and surrounding host environment.174 Hence,
TE is a promising approach for the regeneration of articular
cartilage as it might provide the tools to overcome the limi-
tations observed with the current treatments.175
Osteochondral regeneration
Cartilage and bone arise from a common progenitor and
exist in apposition at articular surfaces of synovial joints as
well as in the epiphyseal growth plate.176 Structurally, the
osteochondral interface is the connection between a layer of
hyaline cartilage and underlying bone and it is crucial for
load transfer between bone and cartilage.6 Moreover, it has
been shown that the osteochondral interface is critical to
maintain the integrity of cartilage by simultaneously limiting
vascular ingrowth from the subchondral bed and preventing
ectopic mineralization.177 The interface typically is charac-
terized by a decreased amount of water content and collagen
type II in comparison with the more superficial layers of
cartilage. Moreover, the collagen fiber diameter is also in-
creased and perpendicular in direction with respect to the
articulating surface.178
Osteochondral tissue is comprised of osteoblasts, osteo-
clasts, and chondrocytes, but as these phases merge, there is
an overlap in cellular function. Hence, this interface is
composed of hypertrophic chondrocytes embedded in a
mineralized cartilage matrix.5,177 While the chondral repair
mechanism relies on the intrinsic healing capabilities of
chondrocytes, osteochondral defects allow the recruitment of
progenitor cells from bone marrow to assist regeneration of
cartilage and underlying bone structure.179
Osteochondral defects penetrate through the vascularized
subchondral bone and spontaneous repair occurs as mesen-
chymal chondroprogenitor cells invade the lesion and form
cartilage. However, full-thickness defect repair is only tran-
sient. The neo-formed tissue is fibrous and enriched in col-
lagen type I and fibronectin and does not have the functional
properties of native hyaline cartilage.4,29,180
For the treatment of large osteochondral defects, one of the
options is autologous osteochondral grafts such as those
used in mosaicplasty.170,181,182 However, donor-site mor-
bidity and lack of integration can compromise long-term
graft outcomes.183 Presently, a significant barrier to clinical
translation is how to achieve functional integration of tissue-
engineered orthopedic grafts.184
The concept of osteochondral TE, a hybrid of bone and
cartilage regeneration, has attracted considerable attention,
particularly as a technique for promoting superior cartilage
integration and as a treatment for osteochondral de-
fects.179,185–196 For osteochondral scaffolds, additional design
criteria should be considered to achieve the best possible
simultaneous growth of the two independent tissues in-
volved. This may require the use of biphasic constructs with
gradients of mechanical, structural, and molecular proper-
ties.154,177,197–200 The most common approach consists in the
development of independent layers for each zone, because
chondrocytes and bone cells show distinct metabolic and
structural functionality, yet communicating and interacting
in a unique culturing system.201 The junction of two layers
has been achieved by fibrin sealant, simple press-fitting,
suturing, or external fixation.179 These scaffolds constitute
the first generation of stratified scaffolds.183 A scaffold with a
predesigned inhomogeneity can better sustain and transmit
the distribution of complex loads inherent at the multitissue
interface and several studies have reported new designs to
fulfill this request.202–206 Constructs to be used for regener-
ation of osteochondral defects may also benefit from the
application of hierarchically and structurally organized drug
delivery systems. One area of special importance in os-
teochondral graft design is the regeneration of the bone to
cartilage interface or a calcified cartilage layer between bone
SKELETAL TISSUE HEALING AND VARIABLES FOR THE DESIGN OF DELIVERY SYSTEMS 311
and cartilage regions, which is critical for graft integration
and for establishing long-term functionality.183
Signaling molecules on natural cascades of bone,
cartilage, and osteochondral formation/healing
Bone. During bone formation, mobile cues directing cell
behavior in bone can be produced by local osteoblasts or
delivery via blood stream. These GFs have indisputable roles
in osteoblast proliferation, differentiation, and subsequent
bone formation and regulation.17,207–209 These molecules act
through autocrine and paracrine signaling mechanisms to
induce the migration, proliferation, and differentiation of
osteoprogenitor cells and/or synthesis of collagen type I and
matrix apposition by mature osteoblasts.210 Upon matrix
destruction, either caused by natural bone remodeling pro-
cess or bone fracture, these factors are released to initiate
osseous healing and to maintain the cyclic anabolic and
catabolic processes that continuously remodel bone.210
The local concentration of chemical cues that can influence
bone cells increases substantially in the event of an injury.
Bone tissue injury initiates a cascade of events leading to the
migration of neutrophils, macrophages, and fibroblasts,
which subsequently express and secrete a variety of cyto-
kines and transcriptional factors, which direct migration of
MSCs, neovascularization, and remodeling/healing.17,211
Moreover, immobilized bone ECM macromolecules act as
primary chemical effectors in cell signaling and functionality.
Several bone ECM proteins contain progenitor and osteo-
blast integrin-binding sites and GF-binding sites, presenting
an obvious selection for developing scaffolds for bone.17
Many GFs, such as BMPs,212 basic FGF (bFGF),213 IGF,214
TGF-b,215 PDGF,216 and vascular endothelial growth factor
(VEGF),217 have been found to induce new bone through
their effects on the recruitment, proliferation, and differen-
tiation of bone-forming cells.218 Their role in bone morpho-
genesis and regeneration is described in Table 1 and their
expression profile is shown in Figure 2. It is likely that
multiple factors regulating distinct aspects of the regenera-
tive process can be used in parallel to affect the regeneration
of functional tissues.219
Cytokines are included in this group of factors and they
are mainly involved in systemic processes, such as host de-
fense and homeostasis, including interleukins (ILs), which
are proinflammatory molecules involved in bone resorption
and remodeling.76 Cytokines encompass a large family of
immunomodulating agents playing key roles in the cross talk
between the immune and skeletal systems.57 Bone fracture is
an injury that initiates an inflammatory response that peaks
24 h following the injury and is complete by the first week.110
During this time, a complex cascade of proinflammatory
signals and GFs are released in a temporally and spatially
controlled manner.110
Bone fracture stimulates expression of several dozen in-
flammatory cytokines, including several isoforms of ILs. IL-
1, IL-6, as well as tumor necrosis factor-alpha (TNF-a) are
shown to play a key role in initiating the repair cascade. They
have a chemotactic effect on other inflammatory cells and on
the recruitment of MSCs.220
Levels of most inflammatory mediators return to baseline
after the week-long acute inflammatory phase.109 Other rel-
evant bioactive factors acting on the morphogenesis of these
tissues include hormones known for controlling serum cal-
cium concentrations and stimulating osteoblast proliferation
and differentiation.76
During bone regeneration there is a temporal sequence of
GFs and cytokines expression.63,234,235 Angiogenic GFs are
predominantly expressed during the early phases to re-
establish vascularity, whereas osteogenic GFs are continu-
ously expressed during bone formation and remodeling.219
Numerous GFs are involved in angiogenesis, including
VEGF,236 FGF-2,237 PDGF,238 Ang-1,239 and -2,240 IGF,241
among others.124
During normal bone healing, VEGF expression was shown
to peak in early days with high expression from days 5 to 14,
while BMP expression peaked at a later time point. Since
establishment of a vascular bed is an early event that pre-
cedes the formation of bone, a similar temporal release
profile should be designed to promote bone regenera-
tion.242,243 VEGF is likely produced by inflammatory cells as
well as mesenchymal progenitors that are recruited to the
site of bone injury. VEGF expression can also be driven to
hypoxia as VEGF represents a target gene of hypoxia-in-
ducible factor.111
Despite extensive studies on the biology and delivery of
GFs, only two formulations are currently approved by the
Food and Drug Administration (FDA) for clinical use in
USA. BMP2 (InfuseTM, Medtronic Sofamor Danek, Inc.) and
BMP7 (OP-1TM, Stryker Biotech) repair injuries by mediating
spinal fusion or fracture healing.244,245
During fracture repair, BMPs are produced by MSCs,
osteoblasts, and chondroblasts, and trigger a cascade of
events, such as proliferation and differentiation of MSCs,
angiogenesis, and synthesis of the ECM.246 BMP-2 acts on
global cellular mobilization and it is also present during the
later stages of osteogenesis and chondrogenesis, whereas
BMP-7 acts on osteogenic differentiation.246 Given that
BMPs are not tissue specific, their localized, targeted, and
controlled delivery is required to prevent any undesired
and uncontrolled bone formation in inadequate tissues of
the body.247
In human clinical treatments, large doses of BMPs (2–
12mg) have been used,248–251 which exceed by far the normal
physiological concentrations of these proteins (18.8–22 pg/
mL)252 in bone defect areas. As an example, the concentra-
tion of BMP-2 approved for application in spine fusion is
1.5mg/mL.251 Therefore, it is clear that the collagen carriers
used in the FDA-approved formulations mentioned above
are less effective in providing structural integrity, effective
mechanotransduction in large nonunion sites, and control
over release kinetics.253 Furthermore, BMP-2 is a well-known
chemoattractant for lymphocytes, monocytes, and macro-
phages and it has also been reported that rapid release of
BMP-2 in high doses can induce transient osteoclast-medi-
ated resorption before new bone formation occurs in meta-
physeal defects.251,254 The role of the carrier on the outcome
of the delivery therapy has been evaluated and the effective
and therapeutic doses change according to the carrier, thus
highlighting its relevant function.255,256
While the current landscape of GFs used for bone re-
generation is dominated by BMPs, a number of other GFs
are being investigated for their potential to regenerate
bone.245 It has been reported that TGF-b1 promotes osteo-
genic differentiation in the early and late stages of
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ectopic bone formation despite its inhibitory effects
in vitro.257 FGF-2 displays a dual role, acting both on the
stimulation of angiogenesis and osteogenesis.111 It is sug-
gested that (FGF/FGF receptor) signaling pathways coor-
dinates a bone anabolic effect by simultaneously activating
Runx2 and BMP-2 pathways.231 The sequential supple-
mentation of FGF-2 followed by BMP-2 tends to enhance
bone phenotype markers.258 While BMP-2 acts mainly on
the osteoblastic differentiation, FGF-2 promotes cell prolif-
eration, increasing the cell population that will be influ-
enced by the action of BMP-2.259
Factors that drive mobilization of BMSCs have been un-
clear, but one of the earliest consequences of a bone fracture
or injury is local tissue hypoxia. Multipotential MSCs are
mobilized into peripheral blood and the Stromal-Derived
Factor-a (SDF-a) is known for its role in stem cell homing,
mobilization of endothelial progenitor cells, and hemato-
poietic stem cells to the injury site.260
Table 1. Growth Factors Roles on Bone and Cartilage Formation and Healing
Growth factor Role on bone formation/healing Role on cartilage formation/healing
BMPs Most osteoinductive GFs223 Induction of Sox9 expression
Promotion of migration, proliferation, and
osteogenic differentiation of MSCs57,221–223
Initiation and regulation of embryonic
development and morphogenesis of cartilage
Influence on skeletal pattern formation.222 Proliferation and maturation of chondrocytes
Strong induction of chondrogenic differentiation
of MSCs by isoform 2
TGF-bs Chemoattractant for osteoprogenitor
cells57,73,221,223
Promotion of collagen, osteonectin, and
osteopontin production221,223
Stimulation of undifferentiated MSCs
proliferation73,222
Inhibition of mature and progenitor osteoclast
cells proliferation221
Inhibition of matrix metalloproteinases, known
for their role on ECM digestion
Stabilization of new blood vessels
Direction of BMSCs toward resorption sites
Induction of Sox9 expression
Initiation of matrix proteins aggrecan and COMP
expression
Enhancement of chondrocyte proliferation
by isoforms 2 and 3
Stimulation of chondrogenic differentiation
of MSCs by isoforms 1 and 3
Inhibition of the activity of MMPs by isoform 1147
Isoform 3 is imperative for Sox9 expression,
but it is not required for continued expression
of chondrogenic markers at later stages
of chondrogenesis
IGF-I Stimulation of osteoprogenitors proliferation73
and bone matrix production221,222
Stimulatory effects on osteoblast activity and
chemotaxis and antiapoptotic effect on
preosteoblasts57
Upregulation of collagen type I
Inflammation mediator
Stimulation of anabolic activity and proliferation
of chondrocytes147,151
Chondrogenic differentiation of MSCs
Stimulation of ECM production151
Protection of ECM from IL-1 and TNF-a-mediated
degradation during cartilage injury147
FGF-2 Stimulation of migration, proliferation, and
differentiation of mature and progenitor
osteoblasts57,73,111,221
Differentiation stage-specific effect
Stimulation of angiogenesis through activation
of capillary endothelial cells and fibroblasts223
Activation of pathways ultimately leading to the
upregulation of Sox9
Promotion of cell proliferation4,147 and inhibition
of chondrogenic differentiation
PDGF Chemotactic and mitogenic effects (precursor
and mature endothelial cells and
inflammatory cells)57,73,111,222,223
Maturation of blood vessels by the recruitment
of SMCs to the endothelial lining
Upregulation of VEGF expression.
Maintenance of hyaline-like cartilage phenotype
Enhancement of chondrocyte proliferation and
proteoglycan synthesis147
VEGF Essential for endochondral bone formation due
to its ability to induce migration and
differentiation of osteoblasts116
Initiatior of angiogenesis. Formation and
maintenance of blood vessels57,111,223
Recruitment of circulating endothelial
progenitor cells and inhibition of endothelial
cells apoptosis111,223
Information was collected from Refs.4,57,73,76,111,116,147,151,221–233
BMSCs, bone marrow mesenchymal stem cells; BMP, bone morphogenetic protein; COMP, cartilage oligomeric matrix protein; ECM,
extracellular matrix; FGF, fibroblast growth factor; GFs, growth factors; IL, interleukin; IGF, insulin growth factor; MMPs, matrix
metalloproteinases; MSCs, mesenchymal stem cells; SMC, smooth muscle cells; TGF, transfoming growth factor; TNF, tumor necrosis factor;
VEGF, vascular endothelial growth factor.
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Cartilage. In cartilage repair, the most investigated GFs
include TGF-b, BMPs, and IGF-I.147,148,261 Further details on
the role of the most significant GFs acting on cartilage can be
found further in Table 1 and Figure 3. Despite the amount of
publications reporting the effect of specific GFs on chon-
drocytes and chondrogenic differentiation of stem cells, little
is known about GFs regulating cartilage wound healing and,
specifically, the spatial and temporal expression of GFs in
acute cartilage wound healing.262 Most of the information
regarding TE of cartilage was provided by the study of
growth plate of long bones. However, it is admitted that the
knowledge of fetal development can provide relevant in-
sights for regenerative medicine purposes as regeneration
partially recapitulates several developmental steps.263,264
In early embryological development, Sox9 is required for
the aggregation of MSCs. Moreover, this transcription factor
is also required for the expression of collagen II and
aggrecan, two of the most important ECM components in
hyaline cartilage.261
Active TGF-b1, 2, and 3 are generally considered to be
potent stimulators of proteoglycans and collagen type II
synthesis.265 During acute cartilage wound healing (Fig. 3B),
TGF-b1 and TGF-b3 are highly expressed, particularly dur-
ing the first 2 weeks upon injury.262 Despite the powerful
ability of TGF-b1 to repair damaged cartilage, high dose of
intra-articular injections of the GF resulted in chemotaxis and
activation of inflammatory cells, promoting fibrosis. Ad-
ditionally, TGF-b1 has been shown to regulate the autocrine/
paracrine axis of IGF-I.266 Hence, drug delivery systems with
fine tuning over dosage and rate of delivery are required to
fulfill the potential of these bioactive agents.267
In fact, intra-articular injections of specific drugs have
failed to produce the desired therapeutical outcomes. The
high reactivity of synovium and rapid efflux of drugs from
the joint cavity have impaired the effect of bioactive agents
injected directly into the articular cartilage.268
Numerous GFs are needed to properly sequence chon-
drogenesis and it is unlikely that any single GF will lead to
complete cartilage repair or affect the arthritic milieu, but
rather a combination in a synergistic approach will be re-
quired.147 There is considerable cross talk between the TGF
and BMP signaling pathways and simultaneous activation of
both seems to promote chondrogenic maturation.227
Combined treatments of TGF-b1 with BMP-2 and IGF-I
have led to the enhancement of glycosaminoglycan deposi-
tion and mechanical properties.175 However, the most
serious limitations of the use of MSCs for chondrogenic
differentiation through the supplementation with bioactive
factors reside on the fact that cell differentiation do not stop
at the prehypertrophic stage.263
Osteochondral interface. Hypertrophic chondrocytes are
the resident cell population identified at the native os-
teochondral interface.206 As described in Figure 3, after dif-
ferentiation and maturation of cells toward the chondrocyte
phenotype, Osterix and Runx2 become upregulated and
chondrocytes achieve their hypertrophic state. At this stage,
collagen type X is highly expressed. The osteochondral in-
terface is also composed by a mineralized and vascularized
matrix, in which angiogenic factors, such as VEGF and FGF-
2, are upregulated.269,270 However, much interest has been
centered on BMPs to promote osteochondral tissue formation
as these molecules have a powerful effect in stimulating both
new bone and cartilage formation.271
In conclusion, natural processes are multifactorial and
skeletal morphogenesis and regeneration are typically driven
by the concomitant action of multiple factors that can work
synergistically on the same process. Release kinetics are
dependent on the type of tissue and defect.210,272
Besides the presentation of the appropriate factor or
combination of factors, the concentration and duration of
function are critical parameters involved in promoting neo-
tissue formation. Concentrations of GFs should be used
within a therapeutic range, whereas crossing the dosage
limits would result either in an inefficient strategy or in the
production of an abnormal tissue.272
FIG. 2. Temporal sequence of growth factors (GFs) and
cytokines expression during bone regeneration. The solid
dash line represents the inflammatory sequence of events,
peaking early upon the injury with high expression of cyto-
kines, such as tumor necrosis factor (TNF)-a, interleukin (IL)-
1, -6, -11, and -18, and angiogenic molecules Angiopoietin-1
(Ang-1) and Ang-2. These molecules are involved in the
stimulation of cell migration, production of cartilaginous
callus, and vascular endothelial growth factor (VEGF) pro-
duction. The square dot line represents the chondrogenic
route that leads to the generation of a cartilaginous callus
peaking between 7 and 14 days after injury. Transfoming
growth factor (TGF)-b1 and Growth differentiation factor-8
(GDF-8) act early in this step, with other isoforms responsible
for chondrogenesis and endochondral ossification peaking
later in the cycle. The long dash double dot line represents the
osteogenic sequence of molecules acting on the formation of a
bony callus. Simultaneously to the expression of chondro-
genic markers, bone morphogenetic protein (BMP)-2, BMP-7,
and stromal cell-derived factor-a (SDF-a) are responsible for
inducing the migration of mesenchymal stem cells (MSCs)
with fibroblast growth factor (FGF)-2 stimulating their pro-
liferation. As callus chondrocytes proliferate, they become
hypertrophic and express high levels of VEGF, promoting the
invasion of blood vessels, leading to the tissue vasculariza-
tion. During this step, TNF-a initiates chondrocyte apoptosis
and promotes the recruitment of MSCs with osteogenic
potential. Moreover, this cytokine is also involved in bone
remodeling, the last step in which the hard callus undergoes a
resorptive phase to form the typical lamellar bone structure
with a central medullar cavity.201–203
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Controlled Release Strategies: The Need
for Spatiotemporal Control
The delivery of multiple GFs has been pursued through
application of different methodologies, making use of the
great versatility of delivery systems developed over the last
decades. However, biological mechanisms of tissue regen-
eration are more complex and, thus, require more than a
particular temporal sequence of therapeutic agents, with
some regenerative tasks demanding tight coordination of the
spatial and temporal presentation of multiple factors.219
GF signaling in tissue healing involves precise regulation
of the concentration, temporal gradient, and spatial gradient
of factors, which ultimately determines the outcome of the
regenerative therapy.124 Controlling the location of release
can create concentration gradients by diffusion of the factors
from the release site.272 The osteochondral interface is a
paramount example of this scenario. The regulation of con-
centration and delivery rates is also particularly relevant as a
suboptimal delivery system does not exploit the full poten-
tial of the released bioactive factor, thus requiring higher
dosages to provide the desired effect.254
Systems releasing drugs acting synergistically provide a
highly inductive therapeutic option, replicating more accu-
rately developmental osteogeonic and chondrogenic cas-
cades, which will ultimately result in a superior clinical
performance using considerably reduced doses of GFs.
However, this will be achieved at the cost of greatly increased
complexity.273 Some of the materials used to produce the
carriers for GFs may provide additional favorable properties
by themselves, such as calcium phosphates or other ions for
bone regeneration, which might not be enhanced by the ad-
dition of specific bioactive agents.274 The combination of
stimulus is not straightforward and the outcomes of the
combination are most of the times unexpected. Hierarchical
systems,275–277 multiple layer systems,278,279 and intelligent
hydrogels280,281 have been developed aiming for the simul-
taneous and/or sequential release of multiple signaling
molecules.
The spatial organization of the GFs in the matrix is critical
because the retention of the molecular bioactivity is also
affected by several parameters, including interactions be-
tween the biomaterial and the GF, the influence of pH and
temperature and porosity.207,282
FIG. 3. (A) Chondrogenic differentiation of MSCs, which involves three main stages influenced mainly by the Sox family
transcription factors, followed by the ossification process. Once chondrocytes reach their mature phenotypic state, osteogenic
transcription factors Osterix and Runx 2 are expressed and chondrocytes evolve to a hypertrophic state. Different GFs are
expressed by cells, depending on their differentiation state. BMP-2 is expressed throughout the process, while TGF-b family is
highly expressed during the MSCs condensation step. The mechanism here described occurs in the growth plate of long
bones and it is responsible for the endochondralossification for bone turn-over. Adapted from 236,243 (B). Cartilage layers
expressing TGF-b1 and TGF-b3 increased between day 1 and 3 and TGF-b1 maintained approximately those levels until day
14. An increase of insulin growth factor (IGF)-I and FGF-2 was observed between day 3 and 7. IGF-I, FGF-2, and TGF-b3
reached a new peak level at day 7 and showed gradual decrease afterward. At day 28, GF expression returned to basal levels.
Color images available online at www.liebertpub.com/teb
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Spatial gradients of factors in scaffolds can be controlled
by varying the positioning of polymer vehicles, immobilizing
ligands on polymer networks to attract target cell popula-
tions, or designing delivery systems to provide spatially
distinct cues.124 Current knowledge of the signals within the
microenvironment that regulate cell fate has led to the de-
velopment of increasingly sophisticated constructs. Scaffolds
with precisely controlled architectures regulating spatio-
temporal release of GFs and morphogens and responding
dynamically to environmental cues have been increasingly
developed.283
Spatial patterns in tissues are controlled by both the ar-
chitectural features of the ECM and concentration profiles
and gradients of diffusible bioactive factors.284 The ability to
combine topographical and biochemical cues within a single
scaffold presents a valuable opportunity to evaluate their
synergistic impact.285
Angiogenesis is paramount of the relevance of a temporal
sequence of bioactive factors expression. Certain factors
initiate angiogenesis, while others induce maturation of
newly formed vessels.286 Later on, a third group of mole-
cules act on the maintenance of the integrity of the estab-
lished vasculature.287 If the appropriate presence and
sequence of bioactive factors are not achieved, poor vascu-
larization occurs.283
Scaffolds can perform the dual roles of biomechanical and
biochemical support by presenting the appropriate media-
tors to the surrounding tissue. The ultimate goal is to de-
velop a multifunctional support performing two main roles:
(1) acting as a temporary structure for cell attachment and
colonization; (2) acting as a delivery platform for multiple
GFs to stimulate tissue regeneration.
Many techniques have been developed to regulate the
kinetics and distribution of soluble factors, including multi-
ple levels of encapsulation and noncovalent bonding of
bioactive factors to peptides with a range of dissociation
constants mimicking ECM immobilization of GFs.283 One of
the most used approaches involves the use of the scaffold as
a controlled release platform by the simple dispersion of
bioactive agents in the matrix or via immobilization to the
scaffold by electrostatic interactions or covalent bonding.284
These monolithic scaffolds, even when combined with GFs
and cells, are still far from leading to successful tissue re-
construction in clinical settings, mainly due to the limited
control exerted over biodegradation and drug delivery.288
Incorporation of GFs into preformed scaffolds has the
advantage that the optimized conditions for scaffold pro-
cessing are not substantially affected by the presence of
proteins. Moreover, the biological activity of the protein can
be preserved.43 However, typically, only small amounts of
proteins can be attached and their release profile becomes
unpredictable. Therefore, scaffold bioactivation is increas-
ingly being accomplished through the incorporation of pre-
formed GF-loaded delivery systems, such as polymeric
particles instead of through direct incorporation, as demon-
strated in Figure 4.43
Microspheres/nanospheres have been widely used as
tools for controlled drug delivery due to their small dimen-
sions and the corresponding high surface area, high drug
loading efficiency, high reactivity toward surrounding tis-
sues, and high diffusibility and mobility.288 Moreover, their
size allows them to respond quickly to environmental stim-
ulus. Generally, microspheres can be processed into macro-
scopic constructs as (1) a dispersed phase surrounded by a
FIG. 4. Strategies to promote the release of multiple bioactive factors from a matrix. Molecules can be physically dispersed
inside the matrix by dispersion of the factor before the carrier processing or by impregnation postcarrier preparation (A).
Typically, this leads to uncontrolled and fast drug delivery kinetics. One strategy to incorporate multiple bioactive signaling
molecules into a matrix is developing hierarchical multiscale systems by the incorporation of nano- and microscale carriers
into the constructs. The entrapment of the drugs in these carriers might offer an enhanced protection for degradation and
high control over the delivery kinetics. These particulate carriers can be tailored to release bioactive factors in specific kinetics,
allowing either a simultaneous (B) or sequential (C) presentation of signaling molecules. The spatiotemporal controlled
release profiles can also be achieved through the conjugation of the drugs with ligands. Bioactive factors or particulate
carriers can be covalently bound to the matrix, resulting in a more controlled mechanism of incorporation (D). Affinity-bound
systems such as binding through heparin domains are a common approach. These mechanisms can be combined to design
even more complex systems. Moreover, the development of multiscale systems is highly promising as nanoparticles can be
incorporated inside microparticles within the constructs (E), promoting dual or multiple release systems with distinct de-
livery rates. The development of gradients of bioactive factors (F) is also an increasingly used approach. Besides promoting
cell migration and inducing specific cell responses according to the concentration gradients, these systems allow a precise
tailoring over the availability of the desired factor, following a biomimetic approach. Color images available online at
www.liebertpub.com/teb
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continuous matrix289,290; or as (2) building blocks to establish
integral scaffolds without a surrounding matrix by a bottom-
up approach.288,291,292
When included in a scaffold, they can also act as rein-
forcement phase, providing higher mechanical strength and
protecting the drug from in vivo degradation.288 Moreover,
the incorporation of preformed delivery systems allows the
combination of carriers with different release rates, entrap-
ping different drugs, thus showing the potential for tailoring
the availability of multiple signaling molecules at different
preprogrammed rates (Fig. 4).288–290
Some of the advantages of entrapping preformed micro-
particulate delivery systems in TE constructs include the
extra protection of the entrapped drugs to the physical and
chemical adversities inherent to scaffold processing tech-
niques and the fact that it avoids a new scaffold design for
optimization of processing parameters.43 Delivery from
scaffolds loaded with particulate carriers allows to retain the
bioactive factor for an extended time, overcoming the dis-
advantages of the direct immobilization of GF in scaffolds
that have poor control over release rates due to an open pore
structure and exposure of the drug to the medium.43,293
When molded into 3D constructs, the drug delivery capacity
of the carriers is coupled with the structural support pro-
vided by the scaffold. Although in these cases the release is
mostly controlled by the properties of the carriers, the en-
trapment within the hydrogel/scaffold also influences the
delivery.272
The integration of controlled release systems such as
micro- and nanoparticles within scaffolds leads to the
development of hierarchically organized and multifunc-
tional constructs with enhanced ability to control and guide
neotissue formation through the recapitulation of spatial and
temporal microenvironments presented by the ECM.284,294
However, it should be noted that the addition of those car-
riers by themselves into the scaffolding structure might have
a surprisingly large impact on the cell response and should
be considered when designing these structures.295
Following a bottom-up approach, some studies have
shown the possibility of designing highly defined geometries
by the assembly of micro- and nanocarriers.296,297 The bot-
tom-up approach for the generation of new materials has
become increasingly attractive for developing novel engi-
neering scaffolds with precise combination of cells, biomol-
ecules, and synthetic biomaterials. These particles act as
building blocks and can assemble by random packing, while
simultaneously entrapping signaling biomolecules, bioactive
minerals, or cells seeded on the surface.288 However, one
drawback is their poor integrity resulting from weak parti-
cle interactions. To preserve the agglomeration of these
formulations, glues and crosslinkers have been used or even
multilayered films prepared by layer by layer of polyelec-
trolytes.298 Moreover, thermal fusion of the particles into in-
tegrated scaffolds has also been used as an alternative.
Nanoparticles can also assemble by an electrostatic interaction
between oppositely charged spheres—colloidal gels.299–301
Summary
There are several GFs and other bioactive molecules in-
volved in the process of bone, cartilage, and osteochondral
interface regeneration. These signaling molecules are pre-
sented in situ with a specific dosage, spatial distribution, and
temporal sequence and TE strategies are increasingly trying
to mimic these native healing cascades. As expected, this is
not an easy task and mixed results have been obtained in this
field. Part II of this review will report some of the most
relevant studies on the use of single, dual, and multiple GF
delivery in direct and indirect approaches for bone, cartilage,
and osteochondral TE strategies.
Acknowledgments
The authors thank Fundac¸a˜o para a Cieˆncia e Tecnologia
for V.E.Santo’s PhD grant (SFRH/BD/39486/2007). This
work was carried out under the scope of the European FP7
Project Find and Bind (NMP4-SL-2009–229292) and Project
MIT/ECE/0047/2009.
Disclosure Statement
No competing financial interests exist.
References
1. Dutta, R.C., and Dutta, A.K. Comprehension of ECM-cell
dynamics: a prerequisite for tissue regeneration. Biotechnol
Adv 28, 764, 2010.
2. Barre`re, F., Mahmood, T.A., de Groot, K., and van Blit-
terswijk, C.A. Advanced biomaterials for skeletal tissue
regeneration: instructive and smart functions. Mater Sci
Eng R 59, 38, 2008.
3. O’Keefe, R.J., and Mao, J. Bone tissue engineering and re-
generation: from discovery to the clinic-an overview. Tissue
Eng Part B Rev 17, 389, 2011.
4. Ahmed, T.A., and Hincke, M.T. Strategies for articular
cartilage lesion repair and functional restoration. Tissue
Eng Part B Rev 16, 305, 2010.
5. Keeney, M., and Pandit, A. The osteochondral junction and
its repair via bi-phasic tissue engineering scaffolds. Tissue
Eng Part B Rev 15, 55, 2009.
6. Yang, P.J., and Temenoff, J.S. Engineering orthopedic tissue
interfaces. Tissue Eng Part B Rev 15, 127, 2009.
7. Kon, E., Delcogliano, M., Filardo, G., Fini, M., Giavaresi, G.,
Francioli, S., et al. Orderly osteochondral regeneration in a
sheep model using a novel nano-composite multilayered
biomaterial. J Orthop Res 28, 116, 2010.
8. Zhang, S., and Uludag, H. Nanoparticulate systems for
growth factor delivery. Pharm Res 26, 1561, 2009.
9. Salgado, A.J., Coutinho, O.P., and Reis, R.L. Bone tissue
engineering: state of the art and future trends. Macromol
Biosci 4, 743, 2004.
10. Muschler, G.F., Raut, V.P., Patterson, T.E., Wenke, J.C.,
and Hollinger, J.O. The design and use of animal models
for translational research in bone tissue engineering
and regenerative medicine. Tissue Eng Part B Rev 16,
123, 2010.
11. Wallace, J.M., Chen, Q., Fang, M., Erickson, B., Orr, B.G.,
and Banaszak Holl, M.M. Type I collagen exists as a dis-
tribution of nanoscale morphologies in teeth, bones, and
tendons. Langmuir 26, 7349, 2010.
12. Viguet-Carrin, S., Garnero, P., and Delmas, P. The role of
collagen in bone strength. Osteoporos Int 17, 319, 2006.
13. Moro, L., Romanello, M., Favia, A., Lamanna, M.P., and
Lozupone, E. Posttranslational modifications of bone col-
lagen type I are related to the function of rat femoral re-
gions. Calcif Tissue Int 66, 151, 2000.
SKELETAL TISSUE HEALING AND VARIABLES FOR THE DESIGN OF DELIVERY SYSTEMS 317
14. Wang, Y., Azaı¨s, T., Robin, M., Valle´e, A., Catania, C., Le-
griel, P., et al. The predominant role of collagen in the nu-
cleation, growth, structure and orientation of bone apatite.
Nat Mater 11, 724, 2012.
15. Ferreira, A.M., Gentile, P., Chiono, V., and Ciardelli, G.
Collagen for bone tissue regeneration. Acta Biomaterialia 8,
3191, 2012.
16. Liu, Y., Kim, Y.K., Dai, L., Li, N., Khan, S.O., Pashley, D.H.,
et al. Hierarchical and non-hierarchical mineralisation of
collagen. Biomaterials 32, 1291, 2011.
17. Porter, J.R., Ruckh, T.T., and Popat, K.C. Bone tissue en-
gineering: a review in bone biomimetics and drug delivery
strategies. Biotechnol Prog 25, 1539, 2009.
18. Lutolf, M.P., and Hubbell, J.A. Synthetic biomaterials
as instructive extracellular microenvironments for mor-
phogenesis in tissue engineering. Nat Biotechnol 23, 47,
2005.
19. Galbraith, C.G., and Sheetz, M.P. Cell traction. Curr Protoc
Cell Biol 12, 123. 2001.
20. Galbraith, C.G., Yamada, K.M., and Sheetz, M.P. The re-
lationship between force and focal complex development. J
Cell Biol 159, 695, 2002.
21. Sheetz, M.P., Felsenfeld, D.P., and Galbraith, C.G. Cell
migration: regulation of force on extracellular-matrix-in-
tegrin complexes. Trends Cell Biol 8, 51, 1998.
22. Arnsdorf, E.J., Tummala, P., Kwon, R.Y., and Jacobs, C.R.
Mechanically induced osteogenic differentiation–the role of
RhoA, ROCKII and cytoskeletal dynamics. J Cell Sci 122,
546, 2009.
23. Santos, M.I., and Reis, R.L. Vascularization in bone tissue
engineering: physiology, current strategies, major hurdles
and future challenges. Macromol Biosci 10, 12, 2010.
24. Uthgenannt, B.A., Kramer, M.H., Hwu, J.A., Wopenka, B.,
and Silva, M.J. Skeletal self-repair: stress fracture healing by
rapid formation and densification of woven bone. J Bone
Miner Res 22, 1548, 2007.
25. Pelled, G., Ben-Arav, A., Hock, C., Reynolds, D.G., Yazici,
C., Zilberman, Y., et al. Direct gene therapy for bone re-
generation: gene delivery, animal models, and outcome
measures. Tissue Eng Part B Rev 16, 13, 2010.
26. Alman, B.A., Kelley, S.P., and Nam, D. Heal thyself: using
endogenous regeneration to repair bone. Tissue Eng Part B
Rev 17, 431, 2011.
27. Ilizarov, G.A. The principles of the Ilizarov method. Bull
Hosp Jt Dis Orthop Inst 48, 1, 1988.
28. Donos, N., Kostopoulos, L., Tonetti, M., and Karring, T.
Long-term stability of autogenous bone grafts following
combined application with guided bone regeneration. Clin
Oral Implant Res 16, 133, 2005.
29. Cancedda, R., Dozin, B., Giannoni, P., and Quarto, R. Tis-
sue engineering and cell therapy of cartilage and bone.
Matrix Biol 22, 81, 2003.
30. Schroeder, J.E., and Mosheiff, R. Tissue engineering ap-
proaches for bone repair: concepts and evidence. Injury 42,
609, 2011.
31. Salkeld, S.L., Patron, L.P., Barrack, R.L., and Cook, S.D. The
effect of osteogenic protein-1 on the healing of segmental
bone defects treated with autograft or allograft bone. J Bone
Joint Surg Am 83-A, 803, 2001.
32. Floyd, T., and Ohnmeiss, D. A meta-analysis of autograft
versus allograft in anterior cervical fusion. Eur Spine J 9,
398, 2000.
33. Lane, J.G., Tontz, W.L., Ball, S.T., Massie, J.B., Chen, A.C.,
Bae, W.C., et al. A morphologic, biochemical, and biome-
chanical assessment of short-term effects of osteochondral
autograft plug transfer in an animal model. Arthroscopy
17, 856, 2001.
34. Wheeler, D.L., and Enneking, W.F. Allograft bone de-
creases in strength in vivo over time. Clin Orthop Rel Res
435, 36, 2005.
35. Aro, H.T., and Aho, A.J. Clinical use of bone allografts. Ann
Med 25, 403, 1993.
36. Kelly, B.T., Potter, H.G., Deng, X.H., Pearle, A.D., Turner,
A.S., Warren, R.F., et al. Meniscal allograft transplantation
in the sheep knee - Evaluation of chondroprotective effects.
Am J Sports Med 34, 1464, 2006.
37. Homminga, G.N., Bulstra, S.K., Kuijer, R., and Vanderlinden,
A.J. Repair of sheep articular-cartilage defects with a rabbit
costal perichondrial graft. Acta Orthop Scand 62, 415, 1991.
38. Poumarat, G., and Squire, P. Comparison of mechanical
properties of human, bovine bone and a new processed
bone xenograft. Biomaterials 14, 337, 1993.
39. Shahgaldi, B.F., Amis, A.A., Heatley, F.W., McDowell, J.,
and Bentley, G. Repair of cartilage lesions using biological
implants - a comparative histological and biomechanical
study in goats. J Bone Joint Surg Br 73, 57, 1991.
40. Sgaglione, N.A., and Florence, A.S. Bone graft substitute
plug failure with giant cell reaction in the treatment of
osteochondral lesions of the distal femur: a report of 2 cases
with operative revision. Arthroscopy 25, 815, 2009.
41. Zdeblick, T.A., Cooke, M.E., Kunz, D.N., Wilson, D., and
McCabe, R.P. Anterior cervical diskectomy and fusion us-
ing a porous hydroxyapatite bone grat substitute. Spine 19,
2348, 1994.
42. Walsh, W.R., Chapman-Sheath, P.J., Cain, S., Debes, J.,
Bruce WJM, Svehla, M.J., et al. A resorbable porous ceramic
composite bone graft substitute in a rabbit metaphyseal
defect model. J Orthop Res 21, 655, 2003.
43. Chen, F.M., An, Y., Zhang, R., and Zhang, M. New insights
into and novel applications of release technology for peri-
odontal reconstructive therapies. J Control Release 149, 92,
2011.
44. Hu W-W, Ward, B.B., Wang, Z., and Krebsbach, P.H. Bone
regeneration in defects compromised by radiotherapy.
J Dental Res 89, 77, 2010.
45. Strube, P., Sentuerk, U., Riha, T., Kaspar, K., Mueller, M.,
Kasper, G., et al. Influence of age and mechanical stability
on bone defect healing: age reverses mechanical effects.
Bone 42, 758, 2008.
46. Lane, J.G., Healey, R.M., Chen, A.C., Sah, R.L., and Amiel,
D. Can osteochondral grafting be augmented with micro-
fracture in an extended-size lesion of articular cartilage?
Am J Sports Med 38, 1316, 2010.
47. Laurie, S.W., Kaban, L.B., Mulliken, J.B., and Murray, J.E.
Donor-site morbidity after harvesting rib and iliac bone.
Plast Reconstr Surg 73, 933, 1984.
48. Nehrer, S., Domayer, S., Dorotka, R., Schatz, K., Bindreiter,
U., and Kotz, R. Three-year clinical outcome after chon-
drocyte transplantation using a hyaluronan matrix for
cartilage repair. Eur J Radiol 57, 3, 2006.
49. Hamlet, W., Liu, S.H., and Yang, R. Destruction of a cy-
ropreserved meniscal allograft: a case for acute rejection.
Arthroscopy 13, 517, 1997.
50. Glassman, S.D., Dimar, J.R., Puno, R.M., and Johnson, J.R.
Salvage of instrumented lumbar fusions complicated by
surgical wound infection. Spine 21, 2163, 1996.
51. Roychoudhury, A., Parkash, H., and Trikha, A. Functional
restoration by gap arthroplasty in temporomandibular joint
318 SANTO ET AL.
ankylosis: A report of 50 cases. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod 87, 166, 1999.
52. David, L.A., Sandor, G.K., Evans, A.W., and Brown, D.H.
Hyperbaric oxygen therapy and mandibular osteoradio-
necrosis: a retrospective study and analysis of treatment
outcomes. J Can Dent Assoc 67, 384. 2001.
53. Drosse, I., Volkmer, E., Seitz, S., Seitz, H., Penzkofer, R.,
Zahn, K., et al. Validation of a femoral critical size defect
model for orthotopic evaluation of bone healing: a biome-
chanical, veterinary and trauma surgical perspective. Tis-
sue Eng Part C Methods 14, 79, 2008.
54. Perry, C.R. Bone repair techniques, bone graft, and bone
graft substitutes. Clin Orthop Relat Res 360, 71, 1999.
55. Aronson, J. Limb-lengthening, skeletal reconstruction, and
bone transport with the Ilizarov method. J Bone Joint Surg
Am 79, 1243, 1997.
56. Reichert, J.C., Epari, D.R., Wullschleger, M.E., Saifzadeh, S.,
Steck, R., Lienau, J., et al. Establishment of a preclinical
ovine model for tibial segmental bone defect repair by
applying bone tissue engineering strategies. Tissue Eng
Part B Rev 16, 93, 2010.
57. Kempen, D.H., Creemers, L.B., Alblas, J., Lu, L., Verbout,
A.J., Yaszemski, M.J., et al. Growth factor interactions in
bone regeneration. Tissue Eng Part B Rev 16, 551, 2010.
58. Dawson, J.I., and Oreffo, R.O. Bridging the regeneration
gap: stem cells, biomaterials and clinical translation in
bone tissue engineering. Arch Biochem Biophys 473, 124,
2008.
59. Lenz, A., Franklin, G.A., and Cheadle, W.G. Systemic in-
flammation after trauma. Injury 38, 1336, 2007.
60. Shapiro, F. Bone development and its relation to fracture
repair. The role of mesenchymal osteoblasts and surface
osteoblasts. Eur Cell Mater 15, 53, 2008.
61. Marzona, L., and Pavolini, B. Play and players in bone
fracture healing match. Clin Cases Miner Bone Metab 6,
159, 2009.
62. Raiche, A.T., and Puleo, D.A. Cell responses to BMP-2 and
IGF-I released with different time-dependent profiles.
J Biomed Mater Res A 69, 342, 2004.
63. Bourque, W.T., Gross, M., and Hall, B.K. Expression of four
growth factors during fracture repair. Int J Dev Biol 37, 573,
1993.
64. Cho, T.J., Gerstenfeld, L.C., and Einhorn, T.A. Differential
temporal expression of members of the transforming
growth factor beta superfamily during murine fracture
healing. J Bone Miner Res 17, 513, 2002.
65. Cenni, E., Perut, F., and Baldini, N. In vitro models for the
evaluation of angiogenic potential in bone engineering.
Acta Pharmacol Sin 32, 21, 2011.
66. Mackie, E.J., Ahmed, Y.A., Tatarczuch, L., Chen, K.S., and
Mirams, M. Endochondral ossification: how cartilage is
converted into bone in the developing skeleton. Int J Bio-
chem Cell Biol 40, 46, 2008.
67. Ortega, N., Behonick, D.J., and Werb, Z. Matrix remodeling
during endochondral ossification. Trends Cell Biol 14, 86,
2004.
68. Mackie, E.J., Tatarczuch, L., and Mirams, M. The skeleton: a
multi-functional complex organ: the growth plate chon-
drocyte and endochondral ossification. J Endocrinol 211,
109, 2011.
69. Garrett, I.R., Chen, D., Gutierrez, G., Zhao, M., Escobedo,
A., Rossini, G., et al. Selective inhibitors of the osteoblast
proteasome stimulate bone formation in vivo and in vitro.
J Clin Invest 111, 1771, 2003.
70. Lalani, Z., Wong, M., Brey, E.M., Mikos, A.G., and Duke, P.J.
Spatial and temporal localization of transforming growth
factor-b1, bone morphogenetic protein-2, and platelet-
derived growth factor-A in healing tooth extraction sockets
in a rabbit model. J Oral Maxillofac Surg 61, 1061, 2003.
71. Harris, S.E., Bonewald, L.F., Harris, M.A., Sabatini, M.,
Dallas, S., Feng, J.Q., et al. Effects of transforming growth
factor b on bone nodule formation and expression of bone
morphogenetic protein 2, osteocalcin, osteopontin, alkaline
phosphatase, and type I collagen mRNA in long-term cul-
tures of fetal rat calvarial osteoblasts. J Bone Miner Res 9,
855, 1994.
72. Hong, L., Tabata, Y., Miyamoto, S., Yamada, K., Aoyama,
I., Tamura, M., et al. Promoted bone healing at a rabbit skull
gap between autologous bone fragment and the sur-
rounding intact bone with biodegradable microspheres
containing transforming growth factor-beta1. Tissue Eng 6,
331, 2000.
73. Mundy, G.R., Chen, D., Zhao, M., Dallas, S., Xu, C., and
Harris, S. Growth regulatory factors and bone. Rev Endocr
Metab Disord 2, 105, 2001.
74. Bennett, J.H., Moffatt, S., and Horton, M. Cell adhesion
molecules in human osteoblasts: structure and function.
Histol Histopathol 16, 603, 2001.
75. Chai, Y.C., Roberts, S.J., Desmet, E., Kerckhofs, G., van
Gastel, N., Geris, L., et al. Mechanisms of ectopic bone
formation by human osteoprogenitor cells on CaP bioma-
terial carriers. Biomaterials 33, 3127, 2012.
76. Allori, A.C., Sailon, A.M., Pan, J.H., and Warren, S.M.
Biological basis of bone formation, remodeling, and repair-
part III: biomechanical forces. Tissue Eng Part B Rev 14,
285, 2008.
77. Maurer, T., Zimmermann, G., Maurer, S., Stegmaier, S.,
Wagner, C., and Hansch, G.M. Inhibition of osteoclast
generation: a novel function of the bone morphogenetic
protein 7/osteogenic protein 1. Mediators Inflamm 2012,
171209, 2012.
78. Alliston, T., and Chang, J. TGFb and Runx2 calibration of
bone extracellular matrix quality for tissue-specific func-
tion. IBMS BoneKEy 8, 370, 2011.
79. Pitaru, S., Kotev-Emeth, S., Noff, D., Kaffuler, S., and Sa-
vion, N. Effect of basic fibroblast growth factor on the
growth and differentiation of adult stromal bone marrow
cells: Enhanced development of mineralized bone-like tis-
sue in culture. J Bone Miner Res 8, 919, 1993.
80. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki,
K., Deguchi, K., et al. Targeted disruption of cbfa1 results in
a complete lack of bone formation owing to maturational
arrest of osteoblasts. Cell 89, 755, 1997.
81. Kim Y-J, Kim H-N, Park E-K, Lee B-H, Ryoo H-M, Kim S-Y,
et al. The bone-related Zn finger transcription factor Osterix
promotes proliferation of mesenchymal cells. Gene 366,
145, 2006.
82. Suzawa, M., Takeuchi, Y., Fukumoto, S., Kato, S., Ueno, N.,
Miyazono, K., et al. Extracellular matrix-associated bone
morphogenetic proteins are essential for differentiation of
murine osteoblastic cells in vitro. Endocrinology 140, 2125,
1999.
83. Einhorn, T.A., Majeska, R.J., Rush, E.B., Levine, P.M., and
Horowitz, M.C. The expression of cytokine activity by
fracture callus. J Bone Miner Res 10, 1272, 1995.
84. Lamoureux, F., Baud’huin M, Duplomb, L., Heymann, D.,
and Re´dini, F. Proteoglycans: key partners in bone cell
biology. Bio Essays 29, 758, 2007.
SKELETAL TISSUE HEALING AND VARIABLES FOR THE DESIGN OF DELIVERY SYSTEMS 319
85. Zhu, J.X., Sasano, Y., Takahashi, I., Mizoguchi, I., and
Kagayama, M. Temporal and spatial gene expression of
major bone extracellular matrix molecules during embry-
onic mandibular osteogenesis in rats. Histochem J 33, 25,
2001.
86. Nordahl, J., Mengarelliwidholm, S., Hultenby, K., and Re-
inholt, F.P. Ultrastructural immunolocalization of fibro-
nectin in epiphyseal and metaphyseal bone of young rats.
Calcif Tissue Int 57, 442, 1995.
87. Takeuchi, Y., Kodama, Y., and Matsumoto, T. Bone matrix
decorin binds transfoming growth factor beta and enhances
its bioactivity. J Biol Chem 269, 32634, 1994.
88. Chen, X.D., Allen, M.R., Bloomfield, S., Xu, T., and Young,
M. Biglycan-deficient mice have delayed osteogenesis after
marrow ablation. Calcif Tissue Int 72, 577, 2003.
89. Wang, X., Shen, X., Li, X., and Agrawal, C.M. Age-related
changes in the collagen network and toughness of bone.
Bone 31, 1, 2002.
90. Horner, A., Bord, S., Kemp, P., Grainger, D., and Comp-
ston, J.E. Distribution of platelet-derived growth factor
(PDGF) a chain mRNA, protein, and PDGF-alpha receptor
in rapidly forming human bone. Bone 19, 353, 1996.
91. Hogan BLM. Bone morphogenetic proteins: multifunctional
regulators of vertebrate development. Genes Dev 10, 1580,
1996.
92. Yakar, S., Rosen, C.J., Beamer, W.G., Ackert-Bicknell, C.L.,
Wu, Y.P., Liu, J.L., et al. Circulating levels of IGF-1 directly
regulate bone growth and density. J Clin Invest 110, 771,
2002.
93. Noda, M., and Camilliere, J.J. In vivo stimulation of bone
formation by transforming growth factor-beta. Endo-
crinology 124, 2991, 1989.
94. Toma, C.D., Ashkar, S., Gray, M.L., Schaffer, J.L., and
Gerstenfeld, L.C. Signal transduction of mechanical stimuli
is dependent on microfilament integrity: identification of
osteopontin as a mechanically induced gene in osteoblasts.
J Bone Miner Res 12, 1626, 1997.
95. McKee, M.D., and Nanci, A. Osteopontin: an interfacial
extracellular matrix protein in mineralized tissues. Connect
Tissue Res 35, 197, 1996.
96. Baht, G.S., Hunter, G.K., and Goldberg, H.A. Bone
sialoprotein-collagen interaction promotes hydroxyapatite
nucleation. Matrix Biol 27, 600, 2008.
97. Zhu, X., Eibl, O., Scheideler, L., and Geis-Gerstorfer, J.
Characterization of nano hydroxyapatite/collagen surfaces
and cellular behaviors. J Biomed Mater Res Part A 79A, 114,
2006.
98. Young, M.F., Kerr, J.M., Ibaraki, K., Heegaard, A.M., and
Robey, P.G. Structure, Expression, and Regulation of the
major noncollagenous matrix proteins of bone. Clin Orthop
Rel Res 281, 275, 1992.
99. Hunter, G.K., Hauschka, P.V., Poole, A.R., Rosenberg, L.C.,
and Goldberg, H.A. Nucleation and inhibition of hy-
droxyapatite formation by mineralized tissue proteins.
Biochem J 317 (Pt 1), 59, 1996.
100. Chenu, C., Colucci, S., Grano, M., Zigrino, P., Barattolo, R.,
Zambonin, G., et al. Osteocalcin induces chemotaxis, se-
cretion of matrix proteins, and calcium-mediated intracel-
lular signaling in human osteoclast-like cells. J Cell Biol 127,
1149, 1994.
101. Nam, D., Mau, E., Wang, Y., Wright, D., Silkstone, D.,
Whetstone, H., et al. T-lymphocytes enable osteoblast
maturation via IL-17F during the early phase of fracture
repair. PLoS One 7, e40044, 2012.
102. Rundle, C.H., Wang, H., Yu, H., Chadwick, R.B., Davis,
E.I., Wergedal, J.E., et al. Microarray analysis of gene ex-
pression during the inflammation and endochondral bone
formation stages of rat femur fracture repair. Bone 38, 521,
2006.
103. Rappolee, D.A., Mark, D., Banda, M.J., and Werb, Z.
Wound macrophages express TGF-a and other growth
factors in vivo: analysis by mRNA phenotyping. Science
241, 708, 1988.
104. Hanna, I. Recent advances in mechanobiological modeling
of bone regeneration. Mech Res Commun 42, 22, 2012.
105. Kenneth, J., and Koval, M.D. Orthopaedic Knowledge
Update 7: Home Study Syllabus. 1st edition. New York:
Amer Acad of Orthopaedic Surgeons, 2002.
106. Weber, B., Emmert, M.Y., Schoenauer, R., Brokopp, C.,
Baumgartner, L., and Hoerstrup, S.P. Tissue engineering on
matrix: future of autologous tissue replacement. Semin
Immunopathol 33, 307, 2011.
107. Anderson, J.M., Rodriguez, A., and Chang, D.T. Foreign
body reaction to biomaterials. Semin Immunol 20, 86, 2008.
108. Bischoff, D.S., Sakamoto, T., Ishida, K., Makhijani, N.S.,
Gruber, H.E., and Yamaguchi, D.T. CXC receptor knockout
mice: Characterization of skeletal features and membra-
nous bone healing in the adult mouse. Bone 48, 267, 2011.
109. Mountziaris, P.M., Spicer, P.P., Kasper, F.K., and Mikos,
A.G. Harnessing and modulating inflammation in strate-
gies for bone regeneration. Tissue Eng Part B Rev 17, 393,
2011.
110. Mountziaris, P.M., and Mikos, A.G. Modulation of the in-
flammatory response for enhanced bone tissue regenera-
tion. Tissue Eng Part B Rev 14, 179, 2008.
111. Hankenson, K.D., Dishowitz, M., Gray, C., and Schenker,
M. Angiogenesis in bone regeneration. Injury 42, 556, 2011.
112. Rhinelander, F.W. Tibial blood supply in relation to frac-
ture healing. Clin Orthop Relat Res 105, 34, 1974.
113. Risau, W. Mechanisms of angiogenesis. Nature 386, 671,
1997.
114. Zelzer, E., and Olsen, B.R. Multiple Roles of Vascular En-
dothelial Growth Factor (VEGF) in Skeletal Development,
Growth, and Repair. Current Topics in Developmental
Biology. 65, 169, 2005.
115. Lieu, S., Hansen, E., Dedini, R., Behonick, D., Werb, Z.,
Miclau, T., et al. Impaired remodeling phase of fracture
repair in the absence of matrix metalloproteinase-2. Dis
Models Mech 4, 203, 2011.
116. Huang, Y.C., Kaigler, D., Rice, K.G., Krebsbach, P.H., and
Mooney, D.J. Combined angiogenic and osteogenic factor
delivery enhances bone marrow stromal cell-driven bone
regeneration. J Bone Miner Res 20, 848, 2005.
117. Chen Y-J, Wurtz, T., Wang C-J, Kuo Y-R, Yang, K.D.,
Huang H-C, et al. Recruitment of mesenchymal stem cells
and expression of TGF-b1 and VEGF in the early stage of
shock wave-promoted bone regeneration of segmental de-
fect in rats. J Orthop Res 22, 526, 2004.
118. Masters, K.S. Covalent growth factor immobilization
strategies for tissue repair and regeneration. Macromol
Biosci 11, 1149, 2011.
119. Tabata, Y. Regenerative inductive therapy based on DDS
technology of protein and gene. J Drug Target 14, 483,
2006.
120. Peng, H., Wright, V., Usas, A., Gearhart, B., Shen, H.C.,
Cummins, J., et al. Synergistic enhancement of bone for-
mation and healing by stem cell-expressed VEGF and bone
morphogenetic protein-4. J Clin Invest 110, 751, 2002.
320 SANTO ET AL.
121. Holderfield, M.T., and Hughes, C.C.W. Crosstalk between
vascular endothelial growth factor, notch, and transform-
ing growth factor-beta in vascular morphogenesis. Circ Res
102, 637, 2008.
122. Matsumoto, T., Mifune, Y., Kawamoto, A., Kuroda, R.,
Shoji, T., Iwasaki, H., et al. Fracture induced mobilization
and incorporation of bone marrow-derived endothelial
progenitor cells for bone healing. J Cell Physiol 215, 234,
2008.
123. Lamalice, L., Le Boeuf, F., and Huot, J. Endothelial cell
migration during angiogenesis. Circ Res 100, 782, 2007.
124. Cao, L., and Mooney, D.J. Spatiotemporal control over
growth factor signaling for therapeutic neovascularization.
Adv Drug Deliv Rev 59, 1340, 2007.
125. Freeman, I., and Cohen, S. The influence of the sequential
delivery of angiogenic factors from affinity-binding algi-
nate scaffolds on vascularization. Biomaterials 30, 2122,
2009.
126. Santos, M.I., Unger, R.E., Sousa, R.A., Reis, R.L., and
Kirkpatrick, C.J. Crosstalk between osteoblasts and endo-
thelial cells co-cultured on a polycaprolactone–starch scaf-
fold and the in vitro development of vascularization.
Biomaterials 30, 4407, 2009.
127. Buschmann, J., Welti, M., Hemmi, S., Neuenschwander, P.,
Baltes, C., Giovanoli, P., et al. Three-dimensional co-
cultures of osteoblasts and endothelial cells in DegraPol
foam: histological and high-field magnetic resonance im-
aging analyses of pre-engineered capillary networks in
bone grafts. Tissue Eng Part A 17, 291, 2011.
128. Gerwin, N., Hops, C., and Lucke, A. Intraarticular drug
delivery in osteoarthritis. Adv Drug Deliv Rev 58, 226,
2006.
129. Maroudas, A., Bayliss, M.T., and Venn, M.F. Further
studies on the composition of human femoral head carti-
lage. Ann Rheum Dis 39, 514, 1980.
130. Steward, A., Liu, Y., and Wagner, D. Engineering cell at-
tachments to scaffolds in cartilage tissue engineering. JOM
63, 74, 2011.
131. Klein, T.J., Malda, J., Sah, R.L., and Hutmacher, D.W. Tis-
sue engineering of articular cartilage with biomimetic
zones. Tissue Eng Part B Rev 15, 143, 2009.
132. Keeney, M., Lai, J.H., and Yang, F. Recent progress in
cartilage tissue engineering. Curr Opin Biotechnol 22, 734,
2011.
133. Kim, T.K., Sharma, B., Williams, C.G., Ruffner, M.A.,
Malik, A., McFarland, E.G., et al. Experimental model for
cartilage tissue engineering to regenerate the zonal orga-
nization of articular cartilage. Osteoarthritis Cartilage 11,
653, 2003.
134. Sharma, B., Williams, C.G., Kim, T.K., Sun, D.N., Malik, A.,
Khan, M., et al. Designing zonal organization into tissue-
engineered cartilage. Tissue Eng 13, 405, 2007.
135. Roughley, P.J. The structure and function of cartilage pro-
teoglycans. Eur Cell Mater 12, 92, 2006.
136. Horkay, F., Basser, P.J., Hecht, A.M., and Geissler, E. Gel-
like behavior in aggrecan assemblies. J Chem Phys 128,
135103, 2008.
137. Roughley, P.J., White, R.J., and Mort, J.S. Presence of pro-
forms of decorin and biglycan in human articular cartilage.
Biochem J 318, 779, 1996.
138. Hedlund, H., Mengarelliwidholm, S., Heinegard, D.,
Reinholt, F.P., and Svensson, O. Fibromodulin distribu-
tion and association with collagen. Matrix Biol 14, 227,
1994.
139. Grover, J., Chen, X.N., Korenberg, J.R., and Roughley, P.J.
The human lumican gene - organization, chromosomal,
location and expression in articular cartilage. J Biol Chem
270, 21942, 1995.
140. Hendriks, J., Riesle, J., and van Blitterswijk, C.A. Co-culture
in cartilage tissue engineering. J Tissue Eng Regen Med 1,
170, 2007.
141. Revell, C.M., and Athanasiou, K.A. Success rates and im-
munologic responses of autogenic, allogenic, and xeno-
genic treatments to repair articular cartilage defects. Tissue
Eng Part B Rev 15, 1, 2009.
142. Morales, T.I. Transforming growth factor-beta 1 stimulates
synthesis of proteoglycan aggregates in calf articular car-
tilage organ cultures. Arch Biochem Biophys 286, 99, 1991.
143. van Beuningen, H.M., van der Kraan, P.M., Arntz, O.J., and
van den Berg, W.B. In vivo protection against interleukin-1-
induced articular cartilage damage by transforming growth
factor-beta 1: age-related differences. Ann Rheum Dis 53,
593, 1994.
144. Glansbeek, H.L., van Beuningen, H.M., Vitters, E.L., Mor-
ris, E.A., van der Kraan, P.M., and van den Berg, W.B. Bone
morphogenetic protein 2 stimulates articular cartilage
proteoglycan synthesis in vivo but does not counteract
interleukin-1alpha effects on proteoglycan synthesis and
content. Arthritis Rheum 40, 1020, 1997.
145. Glansbeek, H.L., van Beuningen, H.M., Vitters, E.L., van
der Kraan, P.M., and van den Berg, W.B. Stimulation of
articular cartilage repair in established arthritis by local
administration of transforming growth factor-beta into
murine knee joints. Lab Invest 78, 133, 1998.
146. Martin, I., Vunjak-Novakovic, G., Yang, J., Langer, R., and
Freed, L.E. Mammalian chondrocytes expanded in the
presence of fibroblast growth factor 2 maintain the ability
to differentiate and regenerate three-dimensional cartilagi-
nous tissue. Exp Cell Res 253, 681, 1999.
147. Fortier, L.A., Barker, J.U., Strauss, E.J., McCarrel, T.M., and
Cole, B.J. The role of growth factors in cartilage repair. Clin
Orthop Relat Res 469, 2706, 2011.
148. Goldring, M.B., Tsuchimochi, K., and Ijiri, K. The control of
chondrogenesis. J Cell Biochem 97, 33, 2006.
149. Bhakta, N.R., Garcia, A.M., Frank, E.H., Grodzinsky, A.J.,
and Morales, T.I. The insulin-like growth factors (IGFs) I
and II bind to articular cartilage via the IGF-binding pro-
teins. J Biol Chem 275, 5860, 2000.
150. Becerra, J., Andrades, J.A., Guerado, E., Zamora-Navas, P.,
Lopez-Puertas, J.M., and Reddi, A.H. Articular cartilage:
structure and regeneration. Tissue Eng Part B Rev 16, 617,
2010.
151. Coates, E., and Fisher, J.P. Gene expression of alginate-
embedded chondrocyte subpopulations and their response
to exogenous IGF-1 delivery. J Tissue Eng Regen Med 6,
179, 2011.
152. Sandell, L.J., and Aigner, T. Articular cartilage and changes
in arthritis. An introduction: cell biology of osteoarthritis.
Arthritis Res 3, 107, 2001.
153. Martin, J.A., Brown, T., Heiner, A., and Buckwalter, J.A.
Post-traumatic osteoarthritis: the role of accelerated chon-
drocyte senescence. Biorheology 41, 479, 2004.
154. Mano, J.F., and Reis, R.L. Osteochondral defects: present
situation and tissue engineering approaches. J Tissue Eng
Regen Med 1, 261, 2007.
155. Akizuki, S., Yasukawa, Y., and Takizawa, T. A new method
of hemostasis for cementless total knee arthroplasty. Bull
Hosp Jt Dis 56, 222, 1997.
SKELETAL TISSUE HEALING AND VARIABLES FOR THE DESIGN OF DELIVERY SYSTEMS 321
156. Singh, S., Lee, C.C., and Tay, B.K. Results of arthroscopic
abrasion arthroplasty in osteoarthritis of the knee joint.
Singapore Med J 32, 34, 1991.
157. Beiser, I.H., and Kanat, I.O. Subchondral bone drilling:
a treatment for cartilage defects. J Foot Surg 29, 595,
1990.
158. Sledge, S.L. Microfracture techniques in the treatment of
osteochondral injuries. Clin Sports Med 20, 365, 2001.
159. O’Driscoll, S.W., Keeley, F.W., and Salter, R.B. The chon-
drogenic potential of free autogenous periosteal grafts for
biological resurfacing of major full-thickness defects in joint
surfaces under the influence of continuous passive motion.
An experimental investigation in the rabbit. J Bone Joint
Surg Am 68, 1017, 1986.
160. O’Driscoll, S.W., and Salter, R.B. The repair of major os-
teochondral defects in joint surfaces by neochondrogenesis
with autogenous osteoperiosteal grafts stimulated by con-
tinuous passive motion. An experimental investigation in
the rabbit. Clin Orthop Relat Res 208, 131, 1986.
161. Peterson, L., Minas, T., Brittberg, M., Nilsson, A., Sjogren-
Jansson, E., and Lindahl, A. Two- to 9-year outcome after
autologous chondrocyte transplantation of the knee. Clin
Orthop Relat Res 374, 212, 2000.
162. Brittberg, M., Lindahl, A., Nilsson, A., Ohlsson, C.,
Isaksson, O., and Peterson, L. Treatment of deep cartilage
defects in the knee with autologous chondrocyte trans-
plantation. N Engl J Med 331, 889, 1994.
163. Chen, A.C., Nagrampa, J.P., Schinagl, R.M., Lottman, L.M.,
and Sah, R.L. Chondrocyte transplantation to articular
cartilage explants in vitro. J Orthop Res 15, 791, 1997.
164. Bedi, A., Feeley, B.T., and Williams, R.J., 3rd. Management
of articular cartilage defects of the knee. J Bone Joint Surg
Am 92, 994, 2010.
165. Frisbie, D.D., Trotter, G.W., Powers, B.E., Rodkey, W.G.,
Steadman, J.R., Howard, R.D., et al. Arthroscopic sub-
chondral bone plate microfracture technique augments
healing of large chondral defects in the radial carpal bone
and medial femoral condyle of horses. Vet Surg 28, 242,
1999.
166. Hunziker, E.B. Articular cartilage repair: basic science and
clinical progress. A review of the current status and pros-
pects. Osteoarthritis Cartilage 10, 432, 2002.
167. Chow, J.C., Hantes, M.E., Houle, J.B., and Zalavras, C.G.
Arthroscopic autogenous osteochondral transplantation for
treating knee cartilage defects: a 2- to 5-year follow-up
study. Arthroscopy 20, 681, 2004.
168. Hangody, L., Feczko, P., Bartha, L., Bodo, G., and Kish, G.
Mosaicplasty for the treatment of articular defects of the
knee and ankle. Clin Orthop Relat Res 391Suppl, S328,
2001.
169. Hangody, L., and Fules, P. Autologous osteochondral
mosaicplasty for the treatment of full-thickness defects
of weight-bearing joints: ten years of experimental and
clinical experience. J Bone Joint Surg Am 85-A Suppl 2,
25, 2003.
170. Hangody, L., Kish, G., Karpati, Z., Szerb, I., and Udvar-
helyi, I. Arthroscopic autogenous osteochondral mosaic-
plasty for the treatment of femoral condylar articular
defects. A preliminary report. Knee Surg Sports Traumatol
Arthrosc 5, 262, 1997.
171. Bi, X., Yang, X., Bostrom, M.P., and Camacho, N.P. Fourier
transform infrared imaging spectroscopy investigations in
the pathogenesis and repair of cartilage. Biochim Biophys
Acta 1758, 934, 2006.
172. David-Vaudey, E., Burghardt, A., Keshari, K., Brouchet, A.,
Ries, M., and Majumdar, S. Fourier Transform Infrared
Imaging of focal lesions in human osteoarthritic cartilage.
Eur Cell Mater 10, 51, discussion 60, 2005.
173. Goldring, M.B., and Marcu, K.B. Cartilage homeostasis in
health and rheumatic diseases. Arthritis Res Ther 11, 224.
2009.
174. Fong, E.L., Watson, B.M., Kasper, F.K., and Mikos, A.G.
Building bridges: leveraging interdisciplinary collabora-
tions in the development of biomaterials to meet clinical
needs. Adv Mater 24, 4995, 2012.
175. Elder, B.D., and Athanasiou, K.A. Systematic assessment of
growth factor treatment on biochemical and biomechanical
properties of engineered articular cartilage constructs. Os-
teoarthritis Cartilage 17, 114, 2009.
176. Grayson, W.L., Martens, T.P., Eng, G.M., Radisic, M., and
Vunjak-Novakovic, G. Biomimetic approach to tissue en-
gineering. Semin Cell Dev Biol 20, 665, 2009.
177. Khanarian, N.T., Jiang, J., Wan, L.Q., Mow, V.C., and Lu,
H.H. A hydrogel-mineral composite scaffold for os-
teochondral interface tissue engineering. Tissue Eng Part A
18, 533, 2012.
178. Castro, N.J., Hacking, S.A., and Zhang, L.G. Recent prog-
ress in interfacial tissue engineering approaches for os-
teochondral defects. Ann Biomed Eng 40, 1628, 2012.
179. O’Shea, T.M., and Miao, X. Bilayered scaffolds for os-
teochondral tissue engineering. Tissue Eng Part B Rev 14,
447, 2008.
180. Madry, H., van Dijk, C.N., and Mueller-Gerbl, M. The basic
science of the subchondral bone. Knee Surg Sports Trau-
matol Arthrosc 18, 419, 2010.
181. Jackson, D.W., Scheer, M.J., and Simon, T.M. Cartilage
substitutes: overview of basic science and treatment op-
tions. J Am Acad Orthop Surg 9, 37, 2001.
182. Redman, S.N., Oldfield, S.F., and Archer, C.W. Current
strategies for articular cartilage repair. Eur Cell Mater 9, 23,
discussion 23, 2005.
183. Jiang, J., Tang, A., Ateshian, G.A., Guo, X.E., Hung, C.T.,
and Lu, H.H. Bioactive stratified polymer ceramic-hydrogel
scaffold for integrative osteochondral repair. Ann Biomed
Eng 38, 2183, 2010.
184. Lu, H.H., Subramony, S.D., Boushell, M.K., and Zhang, X.
Tissue engineering strategies for the regeneration of or-
thopedic interfaces. Ann Biomed Eng 38, 2142, 2010.
185. Alhadlaq, A., and Mao, J.J. Tissue-engineered neogenesis of
human-shaped mandibular condyle from rat mesenchymal
stem cells. J Dent Res 82, 951, 2003.
186. Alhadlaq, A., and Mao, J.J. Tissue-engineered osteochon-
dral constructs in the shape of an articular condyle. J Bone
Joint Surg Am 87, 936, 2005.
187. Allan, K.S., Pilliar, R.M., Wang, J., Grynpas, M.D., and
Kandel, R.A. Formation of biphasic constructs containing
cartilage with a calcified zone interface. Tissue Eng 13,
167, 2007.
188. Angele, P., Kujat, R., Nerlich, M., Yoo, J., Goldberg, V., and
Johnstone, B. Engineering of osteochondral tissue with
bone marrow mesenchymal progenitor cells in a deriva-
tized hyaluronan-gelatin composite sponge. Tissue Eng 5,
545, 1999.
189. Cao, T., Ho, K.H., and Teoh, S.H. Scaffold design and
in vitro study of osteochondral coculture in a three-di-
mensional porous polycaprolactone scaffold fabricated by
fused deposition modeling. Tissue Eng 9 Suppl 1, S103,
2003.
322 SANTO ET AL.
190. Elisseeff, J., Puleo, C., Yang, F., and Sharma, B. Advances in
skeletal tissue engineering with hydrogels. Orthod Cra-
niofac Res 8, 150, 2005.
191. Frenkel, S.R., Bradica, G., Brekke, J.H., Goldman, S.M.,
Ieska, K., Issack, P., et al. Regeneration of articular carti-
lage—evaluation of osteochondral defect repair in the
rabbit using multiphasic implants. Osteoarthritis Cartilage
13, 798, 2005.
192. Gao, J., Dennis, J.E., Solchaga, L.A., Awadallah, A.S.,
Goldberg, V.M., and Caplan, A.I. Tissue-engineered fabri-
cation of an osteochondral composite graft using rat bone
marrow-derived mesenchymal stem cells. Tissue Eng 7,
363, 2001.
193. Gao, J., Dennis, J.E., Solchaga, L.A., Goldberg, V.M., and
Caplan, A.I. Repair of osteochondral defect with tissue-
engineered two-phase composite material of injectable
calcium phosphate and hyaluronan sponge. Tissue Eng 8,
827, 2002.
194. Harley, B.A., Lynn, A.K., Wissner-Gross, Z., Bonfield, W.,
Yannas, I.V., and Gibson, L.J. Design of a multiphase os-
teochondral scaffold III: Fabrication of layered scaffolds
with continuous interfaces. J Biomed Mater Res A 92, 1078,
2010.
195. Holland, T.A., Bodde, E.W., Baggett, L.S., Tabata, Y.,
Mikos, A.G., and Jansen, J.A. Osteochondral repair in the
rabbit model utilizing bilayered, degradable oligo(poly
(ethylene glycol) fumarate) hydrogel scaffolds. J Biomed
Mater Res A 75, 156, 2005.
196. Hung, C.T., Lima, E.G., Mauck, R.L., Takai, E., LeRoux,
M.A., Lu, H.H., et al. Anatomically shaped osteochondral
constructs for articular cartilage repair. J Biomech 36, 1853,
2003.
197. Chen, J., Chen, H., Li, P., Diao, H., Zhu, S., Dong, L., et al.
Simultaneous regeneration of articular cartilage and sub-
chondral bone in vivo using MSCs induced by a spatially
controlled gene delivery system in bilayered integrated
scaffolds. Biomaterials 32, 4793, 2011.
198. Nguyen, L.H., Kudva, A.K., Saxena, N.S., and Roy, K.
Engineering articular cartilage with spatially-varying ma-
trix composition and mechanical properties from a single
stem cell population using a multi-layered hydrogel. Bio-
materials 32, 6946, 2011.
199. Dormer, N.H., Singh, M., Zhao, L., Mohan, N., Berk-
land, C.J., and Detamore, M.S. Osteochondral interface
regeneration of the rabbit knee with macroscopic gra-
dients of bioactive signals. J Biomed Mater Res A 100,
162, 2012.
200. Mohan, N., Dormer, N.H., Caldwell, K.L., Key, V.H.,
Berkland, C.J., and Detamore, M.S. Continuous gradients of
material composition and growth factors for effective re-
generation of the osteochondral interface. Tissue Eng Part
A 17, 2845, 2011.
201. Rodrigues, M.T., Gomes, M.E., and Reis, R.L. Current
strategies for osteochondral regeneration: from stem cells
to pre-clinical approaches. Curr Opin Biotechnol 22, 726,
2011.
202. Kon, E., Delcogliano, M., Filardo, G., Pressato, D., Busacca,
M., Grigolo, B., et al. A novel nano-composite multi-layered
biomaterial for treatment of osteochondral lesions: tech-
nique note and an early stability pilot clinical trial. Injury
41, 693, 2010.
203. Liu, C., Han, Z., and Czernuszka, J.T. Gradient collagen/
nanohydroxyapatite composite scaffold: development and
characterization. Acta Biomater 5, 661, 2009.
204. Tampieri, A., Sandri, M., Landi, E., Pressato, D., Francioli,
S., Quarto, R., et al. Design of graded biomimetic
osteochondral composite scaffolds. Biomaterials 29,
3539, 2008.
205. Wahl, D.A., Sachlos, E., Liu, C., and Czernuszka, J.T.
Controlling the processing of collagen-hydroxyapatite
scaffolds for bone tissue engineering. J Mater Sci Mater
Med 18, 201, 2007.
206. Khanarian, N.T., Haney, N.M., Burga, R.A., and Lu, H.H. A
functional agarose-hydroxyapatite scaffold for osteochon-
dral interface regeneration. Biomaterials 33, 5247, 2012.
207. Bessa, P.C., Casal, M., and Reis, R.L. Bone morphogenetic
proteins in tissue engineering: the road from laboratory
to clinic, part II (BMP delivery). J Tissue Eng Regen Med 2,
81, 2008.
208. Kagiwada, H., Yashiki, T., Ohshima, A., Tadokoro, M.,
Nagaya, N., and Ohgushi, H. Human mesenchymal stem
cells as a stable source of VEGF-producing cells. J Tissue
Eng Regen Med 2, 184, 2008.
209. Xiao, C., Zhou, H., Liu, G., Zhang, P., Fu, Y., Gu, P., et al.
Bone marrow stromal cells with a combined expression of
BMP-2 and VEGF-165 enhanced bone regeneration. Biomed
Mater 6, 015013, 2011.
210. Kofron, M.D., Li, X., and Laurencin, C.T. Protein- and gene-
based tissue engineering in bone repair. Curr Opin Bio-
technol 15, 399, 2004.
211. Hoch, A.I., Binder, B.Y., Genetos, D.C., and Leach, J.K.
Differentiation-dependent secretion of proangiogenic fac-
tors by mesenchymal stem cells. PLoS One 7, e35579, 2012.
212. Groeneveld EHJ, and Burger, E.H. Bone morphogenetic
proteins in human bone regeneration. Eur J Endocrinol 142,
9, 2000.
213. Du, X.L., Xie, Y.L., Xian, C.J., and Chen, L. Role of FGFs/
FGFRs in skeletal development and bone regeneration.
J Cell Physiol 227, 3731, 2012.
214. Koch, H., Jadlowiec, J.A., and Campbell, P.G. Insulin-like
growth factor-I induces early osteoblast gene expression in
human mesenchymal stem cells. Stem Cells Dev 14, 621,
2005.
215. Hong, L., Tabata, Y., Miyamoto, S., Yamamoto, M., Ya-
mada, K., Hashimoto, N., et al. Bone regeneration at rabbit
skull defects treated with transforming growth factor-beta
1 incorporated into hydrogels with different levels of bio-
degradability. J Neurosurg 92, 315, 2000.
216. Yu, X.H., Hsieh, S.C., Bao, W., and Graves, D.T. Temporal
expression of PDGF receptors and PDGF regulatory effects
on osteoblastic cells in mineralizing cultures. Am J Physiol
Cell Physiol 272, C1709, 1997.
217. Mayr-Wohlfart, U., Waltenberger, J., Hausser, H., Kessler,
S., Gunther, K.P., Dehio, C., et al. Vascular endothelial
growth factor stimulates chemotactic migration of primary
human osteoblasts. Bone 30, 472, 2002.
218. Fischer, J., Kolk, A., Wolfart, S., Pautke, C., Warnke, P.H.,
Plank, C., et al. Future of local bone regeneration - Protein
versus gene therapy. J Craniomaxillofac Surg 39, 54, 2011.
219. Chen, F.M., Zhang, M., and Wu, Z.F. Toward delivery of
multiple growth factors in tissue engineering. Biomaterials
31, 6279, 2010.
220. Dimitriou, R., Tsiridis, E., and Giannoudis, P.V. Current
concepts of molecular aspects of bone healing. Injury 36,
1392, 2005.
221. Bose, S., and Tarafder, S. Calcium phosphate ceramic sys-
tems in growth factor and drug delivery for bone tissue
engineering: a review. Acta Biomater 8, 1401, 2011.
SKELETAL TISSUE HEALING AND VARIABLES FOR THE DESIGN OF DELIVERY SYSTEMS 323
222. Lieberman, J.R., Daluiski, A., and Einhorn, T.A. The role of
growth factors in the repair of bone. Biology and clinical
applications. J Bone Joint Surg Am 84-A, 1032, 2002.
223. Allori, A.C., Sailon, A.M., and Warren, S.M. Biological basis
of bone formation, remodeling, and repair-part I: bio-
chemical signaling molecules. Tissue Eng Part B Rev 14,
259, 2008.
224. Bessa, P.C., Casal, M., and Reis, R.L. Bone morphogenetic
proteins in tissue engineering: the road from the laboratory
to the clinic, part I (basic concepts). J Tissue Eng Regen Med
2, 1, 2008.
225. Kaully, T., Kaufman-Francis, K., Lesman, A., and Leven-
berg, S. Vascularization—the conduit to viable engineered
tissues. Tissue Eng Part B Rev 15, 159, 2009.
226. Kock, L., van Donkelaar, C.C., and Ito, K. Tissue engi-
neering of functional articular cartilage: the current status.
Cell Tissue Res 347, 613, 2011.
227. Quintana, L., zur Nieden, N.I., and Semino, C.E. Morpho-
genetic and regulatory mechanisms during developmental
chondrogenesis: new paradigms for cartilage tissue engi-
neering. Tissue Eng Part B Rev 15, 29, 2009.
228. Fan, H., Hu, Y., Qin, L., Li, X., Wu, H., and Lv, R. Porous
gelatin-chondroitin-hyaluronate tri-copolymer scaffold
containing microspheres loaded with TGF-beta1 induces
differentiation of mesenchymal stem cells in vivo for en-
hancing cartilage repair. J Biomed Mater Res A 77, 785,
2006.
229. Bian, L., Zhai, D.Y., Tous, E., Rai, R., Mauck, R.L., and
Burdick, J.A. Enhanced MSC chondrogenesis following
delivery of TGF-beta3 from alginate microspheres within
hyaluronic acid hydrogels in vitro and in vivo. Biomaterials
32, 6425, 2011.
230. Mullen, L.M., Best, S.M., Brooks, R.A., Ghose, S., Gwynne,
J.H., Wardale, J., et al. Binding and release characteris-
tics of insulin-like growth factor-1 from a collagen-
glycosaminoglycan scaffold. Tissue Eng Part C Methods
16, 1439, 2010.
231. Kodama, N., Nagata, M., Tabata, Y., Ozeki, M., Ninomiya,
T., and Takagi, R. A local bone anabolic effect of rhFGF2-
impregnated gelatin hydrogel by promoting cell prolifera-
tion and coordinating osteoblastic differentiation. Bone 44,
699, 2009.
232. Meinel, L., Zoidis, E., Zapf, J., Hassa, P., Hottiger, M.O.,
Auer, J.A., et al. Localized insulin-like growth factor I
delivery to enhance new bone formation. Bone 33, 660,
2003.
233. Bhattarai, N., Gunn, J., and Zhang, M. Chitosan-based
hydrogels for controlled, localized drug delivery. Adv
Drug Deliv Rev 62, 83, 2010.
234. Marsell, R., and Einhorn, T.A. The biology of fracture
healing. Injury 42, 551, 2011.
235. Gerstenfeld, L.C., Cullinane, D.M., Barnes, G.L., Graves,
D.T., and Einhorn, T.A. Fracture healing as a post-natal
developmental process: Molecular, spatial, and temporal
aspects of its regulation. J Cell Biochem 88, 873, 2003.
236. Lyons, J.M., Schwimer, J.E., Anthony, C.T., Thomson, J.L.,
Cundiff, J.D., Casey, D.T., et al. The role of VEGF pathways
in human physiologic and pathologic angiogenesis. J Surg
Res 159, 517, 2010.
237. Friesel, R.E., and Maciag, T. Molecular mechanisms of an-
giogenesis - fibroblast growth factor signal transduction.
Faseb J 9, 919, 1995.
238. Battegay, E.J., Rupp, J., Iruelaarispe, L., Sage, E.H., and
Pech, M. PDGF-BB modulates endothelial proliferation and
angiogenesis in vitro via PDGF beta-receptors. J Cell Biol
125, 917, 1994.
239. Kobayashi, K., Kondo, T., Inoue, N., Aoki, M., Mizuno, M.,
Komori, K., et al. Combination of in vivo angiopoietin-1
gene transfer and autologous bone marrow cell implanta-
tion for functional therapeutic angiogenesis. Arterioscler
Thromb Vasc Biol 26, 1465, 2006.
240. Felcht, M., Luck, R., Schering, A., Seidel, P., Srivastava, K.,
Hu, J.H., et al. Angiopoietin-2 differentially regulates an-
giogenesis through TIE2 and integrin signaling. J Clin In-
vest 122, 1991, 2012.
241. Shigematsu, S., Yamauchi, K., Nakajima, K., Iijima, S., Ai-
zawa, T., and Hashizume, K. IGF-1 regulates migration and
angiogenesis of human endothelial cells. Endocrine J 46
Suppl, S59, 1999.
242. Kempen, D.H., Lu, L., Heijink, A., Hefferan, T.E., Creemers,
L.B., Maran, A., et al. Effect of local sequential VEGF and
BMP-2 delivery on ectopic and orthotopic bone regenera-
tion. Biomaterials 30, 2816, 2009.
243. Kanczler, J.M., Ginty, P.J., White, L., Clarke, N.M., Howdle,
S.M., Shakesheff, K.M., et al. The effect of the delivery of
vascular endothelial growth factor and bone morphogenic
protein-2 to osteoprogenitor cell populations on bone for-
mation. Biomaterials 31, 1242, 2010.
244. Senta, H., Park, H., Bergeron, E., Drevelle, O., Fong, D.,
Leblanc, E., et al. Cell responses to bone morphogenetic
proteins and peptides derived from them: biomedical ap-
plications and limitations. Cytokine Growth Factor Rev 20,
213, 2009.
245. Nauth, A., Ristevski, B., Li, R., and Schemitsch, E.H.
Growth factors and bone regeneration: how much bone can
we expect? Injury 42, 574, 2011.
246. Nair, M.B., Kretlow, J.D., Mikos, A.G., and Kasper, F.K.
Infection and tissue engineering in segmental bone
defects—a mini review. Curr Opin Biotechnol 22, 721,
2011.
247. Haidar, Z.S., Hamdy, R.C., and Tabrizian, M. Delivery of
recombinant bone morphogenetic proteins for bone re-
generation and repair. Part B: delivery systems for BMPs in
orthopaedic and craniofacial tissue engineering. Biotechnol
Lett 31, 1825, 2009.
248. Gautschi, O.P., Frey, S.P., and Zellweger, R. Bone mor-
phogenetic proteins in clinical applications. ANZ J Surg 77,
626, 2007.
249. Shields, L.B., Raque, G.H., Glassman, S.D., Campbell, M.,
Vitaz, T., Harpring, J., et al. Adverse effects associated with
high-dose recombinant human bone morphogenetic pro-
tein-2 use in anterior cervical spine fusion. Spine (Phila Pa
1976) 31, 542, 2006.
250. Alonso, N., Tanikawa, D.Y., Freitas Rda, S., Canan, L., Jr.,
Ozawa, T.O., and Rocha, D.L. Evaluation of maxillary
alveolar reconstruction using a resorbable collagen sponge
with recombinant human bone morphogenetic protein-2 in
cleft lip and palate patients. Tissue Eng Part C Methods 16,
1183, 2010.
251. Zara, J.N., Siu, R.K., Zhang, X., Shen, J., Ngo, R., Lee, M.,
et al. High doses of bone morphogenetic protein 2 induce
structurally abnormal bone and inflammation in vivo. Tis-
sue Eng Part A 17, 1389, 2011.
252. Glass, G.E., Chan, J.K., Freidin, A., Feldmann, M., Hor-
wood, N.J., and Nanchahal, J. TNF-alpha promotes fracture
repair by augmenting the recruitment and differentiation of
muscle-derived stromal cells. Proc Natl Acad Sci U S A 108,
1585, 2011.
324 SANTO ET AL.
253. Bae, J.H., Song, H.R., Kim, H.J., Lim, H.C., Park, J.H., Liu,
Y., et al. Discontinuous release of bone morphogenetic
protein-2 loaded within interconnected pores of honey-
comb-like polycaprolactone scaffold promotes bone healing
in a large bone defect of rabbit ulna. Tissue Eng Part A 17,
2389, 2011.
254. Brown, K.V., Li, B., Guda, T., Perrien, D.S., Guelcher, S.A.,
and Wenke, J.C. Improving bone formation in a rat femur
segmental defect by controlling bone morphogenetic pro-
tein-2 release. Tissue Eng Part A 17, 1735, 2011.
255. Boerckel, J.D., Kolambkar, Y.M., Dupont, K.M., Uhrig, B.A.,
Phelps, E.A., Stevens, H.Y., et al. Effects of protein dose and
delivery system on BMP-mediated bone regeneration.
Biomaterials 32, 5241, 2011.
256. Kempen, D.H., Lu, L., Hefferan, T.E., Creemers, L.B.,
Maran, A., Classic, K.L., et al. Retention of in vitro and
in vivo BMP-2 bioactivities in sustained delivery vehicles
for bone tissue engineering. Biomaterials 29, 3245, 2008.
257. Tachi, K., Takami, M., Sato, H., Mochizuki, A., Zhao, B.,
Miyamoto, Y., et al. Enhancement of bone morphogenetic
protein-2-induced ectopic bone formation by transforming
growth factor-beta1. Tissue Eng Part A 17, 597, 2011.
258. Maegawa, N., Kawamura, K., Hirose, M., Yajima, H.,
Takakura, Y., and Ohgushi, H. Enhancement of osteoblastic
differentiation of mesenchymal stromal cells cultured by
selective combination of bone morphogenetic protein-2
(BMP-2) and fibroblast growth factor-2 (FGF-2). J Tissue
Eng Regen Med 1, 306, 2007.
259. Hughes-Fulford, M., and Li, C.F. The role of FGF-2 and
BMP-2 in regulation of gene induction, cell proliferation
and mineralization. J Orthop Surg Res 6, 8, 2011.
260. Higashino, K., Viggeswarapu, M., Bargouti, M., Liu, H.,
Titus, L., and Boden, S.D. Stromal cell-derived factor-1
potentiates bone morphogenetic protein-2 induced bone
formation. Tissue Eng Part A 17, 523, 2011.
261. Vinatier, C., Mrugala, D., Jorgensen, C., Guicheux, J., and
Noe¨l, D. Cartilage engineering: a crucial combination of
cells, biomaterials and biofactors. Trends Biotechnol 27,
307, 2009.
262. Bos, P.K., van Osch, G.J., Frenz, D.A., Verhaar, J.A., and
Verwoerd-Verhoef, H.L. Growth factor expression in
cartilage wound healing: temporal and spatial immuno-
localization in a rabbit auricular cartilage wound model.
Osteoarthritis Cartilage 9, 382, 2001.
263. Freyria, A.M., and Mallein-Gerin, F. Chondrocytes or adult
stem cells for cartilage repair: the indisputable role of
growth factors. Injury 43, 259, 2012.
264. Brochhausen, C., Lehmann, M., Halstenberg, S., Meurer,
A., Klaus, G., and Kirkpatrick, C.J. Signalling molecules
and growth factors for tissue engineering of cartilage-what
can we learn from the growth plate? J Tissue Eng Regen
Med 3, 416, 2009.
265. Redini, F., Galera, P., Mauviel, A., Loyau, G., and Pujol, J.P.
Transforming growth factor b stimulates collagen and
glycosaminoglycan biosynthesis in cultured rabbit articular
chondrocytes. FEBS Lett 234, 172, 1988.
266. Tsukazaki, T., Usa, T., Matsumoto, T., Enomoto, H., Oht-
suru, A., Namba, H., et al. Effect of transforming growth
factor-beta on the insulin-like growth factor-I autocrine/
paracrine axis in cultured rat articular chondrocytes. Exp
Cell Res 215, 9, 1994.
267. van Beuningen, H.M., Glansbeek, H.L., van der Kraan,
P.M., and van den Berg, W.B. Osteoarthritis-like changes in
the murine knee joint resulting from intra-articular trans-
forming growth factor-beta injections. Osteoarthritis Carti-
lage 8, 25, 2000.
268. Edwards, S.H. Intra-articular drug delivery: the challenge
to extend drug residence time within the joint. Vet J 190, 15,
2011.
269. Pesesse, L., Sanchez, C., and Henrotin, Y. Osteochondral
plate angiogenesis: a new treatment target in osteoarthritis.
Joint Bone Spine 78, 144, 2011.
270. Wang, Q.Y., Dai, J., Kuang, B., Zhang, J., Yu, S.B., Duan,
Y.Z., et al. Osteochondral angiogenesis in rat mandibular
condyles with osteoarthritis-like changes. Arch Oral Biol
57, 620, 2012.
271. Panseri, S., Russo, A., Cunha, C., Bondi, A., Di Martino, A.,
Patella, S., et al. Osteochondral tissue engineering approaches
for articular cartilage and subchondral bone regeneration.
Knee Surg Sports Traumatol Arthrosc 20, 1182, 2012.
272. Salvay, D.M., and Shea, L.D. Inductive tissue engineering
with protein and DNA-releasing scaffolds. Mol Biosyst 2,
36, 2006.
273. Ripamonti, U., Ferretti, C., and Heliotis, M. Soluble and
insoluble signals and the induction of bone formation:
molecular therapeutics recapitulating development. J Anat
209, 447, 2006.
274. Luvizuto, E.R., Tangl, S., Zanoni, G., Okamoto, T., Sonoda,
C.K., Gruber, R., et al. The effect of BMP-2 on the osteo-
conductive properties of beta-tricalcium phosphate in rat
calvaria defects. Biomaterials 32, 3855, 2011.
275. Cinar, G., Ceylan, H., Urel, M., Erkal, T.S., Deniz Tekin, E.,
Tekinay, A.B., et al. Amyloid inspired self-assembled Pep-
tide nanofibers. Biomacromolecules 13, 3377, 2012.
276. Shalumon, K.T., Chennazhi, K.P., Tamura, H., Kawahara,
K., Nair, S.V., and Jayakumar, R. Fabrication of three-
dimensional nano, micro and micro/nano scaffolds of po-
rous poly(lactic acid) by electrospinning and comparison of
cell infiltration by Z-stacking/three-dimensional projection
technique. IET Nanobiotechnol 6, 16, 2012.
277. Matson, J.B., and Stupp, S.I. Self-assembling peptide scaf-
folds for regenerative medicine. Chem Commun (Camb)
48, 26, 2012.
278. Chen, Z., Li, Z., Lin, Y., Yin, M., Ren, J., and Qu, X. Bio-
mineralization inspired surface engineering of nanocarriers
for pH-responsive, targeted drug delivery. Biomaterials 34,
1364, 2012.
279. Bae, S.E., Choi, J., Joung, Y.K., Park, K., and Han, D.K.
Controlled release of bone morphogenetic protein (BMP)-2
from nanocomplex incorporated on hydroxyapatite-formed
titanium surface. J Control Release 160, 676, 2012.
280. Lee, S.C., Kwon, I.K., and Park, K. Hydrogels for delivery
of bioactive agents: a historical perspective. Adv Drug
Deliv Rev 2012. [Epub ahead of print] DOI: 10.1016/
j.addr.2012.07.015
281. Lienemann, P.S., Lutolf, M.P., and Ehrbar, M. Biomimetic
hydrogels for controlled biomolecule delivery to augment
bone regeneration. Adv Drug Deliv Rev 64, 1078, 2012.
282. Fan, H., Vitharana, S.N., Chen, T., O’Keefe, D., and Mid-
daugh, C.R. Effects of pH and polyanions on the thermal
stability of fibroblast growth factor 20. Mol Pharm 4, 232,
2007.
283. Sands, R.W., and Mooney, D.J. Polymers to direct cell fate
by controlling the microenvironment. Curr Opin Biotechnol
18, 448, 2007.
284. Biondi, M., Ungaro, F., Quaglia, F., and Netti, P.A. Con-
trolled drug delivery in tissue engineering. Adv Drug Deliv
Rev 60, 229, 2008.
SKELETAL TISSUE HEALING AND VARIABLES FOR THE DESIGN OF DELIVERY SYSTEMS 325
285. Lim, S.H., and Mao, H.Q. Electrospun scaffolds for stem
cell engineering. Adv Drug Deliv Rev 61, 1084, 2009.
286. Chen, R.R., Silva, E.A., Yuen, W.W., and Mooney, D.J.
Spatio-temporal VEGF and PDGF delivery patterns blood
vessel formation and maturation. Pharm Res 24, 258, 2007.
287. Pepper, M.S. Transforming growth factor-beta: vasculo-
genesis, angiogenesis, and vessel wall integrity. Cytokine
Growth Factor Rev 8, 21, 1997.
288. Wang, H., Leeuwenburgh SCG, Li, Y., and Jansen, J.A. The
Use of Micro- and nanospheres as functional components
for bone tissue regeneration. Tissue Eng Part B Rev 18, 24,
2011.
289. Niu, X., Feng, Q., Wang, M., Guo, X., and Zheng, Q. Porous
nano-HA/collagen/PLLA scaffold containing chitosan
microspheres for controlled delivery of synthetic peptide
derived from BMP-2. J Control Release 134, 111, 2009.
290. Perets, A., Baruch, Y., Weisbuch, F., Shoshany, G., Neufeld,
G., and Cohen, S. Enhancing the vascularization of three-
dimensional porous alginate scaffolds by incorporating
controlled release basic fibroblast growth factor micro-
spheres. J Biomed Mater Res A 65, 489, 2003.
291. Shi, X., Su, K., Varshney, R.R., Wang, Y., and Wang, D.A.
Sintered microsphere scaffolds for controlled release and
tissue engineering. Pharm Res 28, 1224, 2011.
292. Wang, X., Wenk, E., Zhang, X., Meinel, L., Vunjak-
Novakovic, G., and Kaplan, D.L. Growth factor gradients
via microsphere delivery in biopolymer scaffolds for
osteochondral tissue engineering. J Control Release 134, 81,
2009.
293. Silva, A.K., Richard, C., Bessodes, M., Scherman, D., and
Merten, O.W. Growth factor delivery approaches in hy-
drogels. Biomacromolecules 10, 9, 2009.
294. Guo, X., Park, H., Young, S., Kretlow, J.D., van den
Beucken, J.J., Baggett, L.S., et al. Repair of osteochondral
defects with biodegradable hydrogel composites encapsu-
lating marrow mesenchymal stem cells in a rabbit model.
Acta Biomater 6, 39, 2010.
295. Ravindran, S., Roam, J.L., Nguyen, P.K., Hering, T.M., El-
bert, D.L., and McAlinden, A. Changes of chondrocyte
expression profiles in human MSC aggregates in the pres-
ence of PEG microspheres and TGF-beta3. Biomaterials 32,
8436, 2011.
296. Duan, B., Wang, M., Zhou, W.Y., Cheung, W.L., Li, Z.Y.,
and Lu, W.W. Three-dimensional nanocomposite scaffolds
fabricated via selective laser sintering for bone tissue en-
gineering. Acta Biomaterialia 6, 4495, 2010.
297. Zhou, W., Lee, S., Wang, M., Cheung, W., and Ip, W. Se-
lective laser sintering of porous tissue engineering scaffolds
from poly(L-lactide)/carbonated hydroxyapatite nano-
composite microspheres. J Mater Sci 19, 2535, 2008.
298. Miranda, E.S., Silva, T.H., Reis, R.L., and Mano, J.F. Na-
nostructured natural-based polyelectrolyte multilayers to
agglomerate chitosan particles into scaffolds for tissue en-
gineering. Tissue Eng Part A 17, 2663, 2011.
299. Wang, H., Hansen, M.B., Lo¨wik DWPM, van Hest JCM, Li,
Y., Jansen, J.A., et al. Oppositely charged gelatin nano-
spheres as building blocks for injectable and biodegradable
gels. Adv Mater 23, H119, 2011.
300. Van Tomme, S.R., van Steenbergen, M.J., De Smedt, S.C.,
van Nostrum, C.F., and Hennink, W.E. Self-gelling hydro-
gels based on oppositely charged dextran microspheres.
Biomaterials 26, 2129, 2005.
301. Wang, Q., Wang, J., Lu, Q., Detamore, M.S., and Berkland,
C. Injectable PLGA based colloidal gels for zero-order
dexamethasone release in cranial defects. Biomaterials 31,
4980, 2010.
Address correspondence to:
Manuela E. Gomes, PhD
3B’s Research Group–Biomaterials
Biodegradables, and Biomimetics
Headquarters of the European Institute of Excellence







Received: March 13, 2012
Accepted: December 11, 2012
Online Publication Date: February 15, 2013
326 SANTO ET AL.
